Novel double-stranded siRNA (small interfering ribonucleic acid) as well as conjugate and application thereof
Novel double-stranded siRNA conjugates with modified nucleotides provide a more effective hepatitis B treatment by enhancing gene silencing efficacy and reducing toxicity, addressing the limitations of current treatments.
Patent Information
- Application Number
- CN202410706089.7
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Priority Date
- 2023-06-01
- Filing Date
- 2024-05-31
- Publication Date
- 2024-12-03
AI Technical Summary
Existing treatments for hepatitis B, such as interferon and nucleoside analogs, face issues like drug resistance and adverse reactions, necessitating a more effective gene silencing mechanism to inhibit viral replication.
Development of novel double-stranded siRNA and its conjugates with modified nucleotides, designed to inhibit hepatitis B virus expression through RNA interference, offering higher gene expression inhibition activity and lower toxicity.
The novel siRNA conjugates effectively silence hepatitis B virus gene expression, potentially reducing viral replication and infection, while minimizing toxicity and resistance.
Smart Images

Figure SMS_3 
Figure SMS_5 
Figure SMS_10
Abstract
Description
Technical Field
[0001] The present invention belongs to the field of small nucleic acid drugs, and the purpose of the present invention is to provide a novel double-stranded siRNA, its conjugate and its use. The present invention also provides the use of the double-stranded siRNA and its conjugate in the preparation of a drug for treating and / or preventing hepatitis B disease. In addition, the present invention also relates to a novel compound, and the application (use) of the compound in the raw material for solid phase synthesis of DNA nucleotides, the synthetic raw material for oligonucleotide drugs, the synthetic raw material for siRNA drugs, siRNA drug research, gene function research and / or the screening of the whole gene library, especially the use as the synthetic raw material for the double-stranded siRNA drug of the present invention. In addition, the present invention also relates to a novel nucleotide residue, and its application in siRNA drug research, gene function research and / or the screening of the whole gene library, and its application as an oligonucleotide embedding group. Background Art
[0002] Hepatitis B virus (also known as hepatitis B or HBV) is a type of infectious disease that poses a serious threat to the world. Currently, the two major types of hepatitis B treatment drugs recognized worldwide are interferon and nucleoside analogs. However, these two types of drugs have many disadvantages such as easy to develop drug resistance or limited use after use. For example, interferon is prone to adverse reactions, and nucleoside drugs have drug resistance and recurrence after drug withdrawal. Therefore, if the gene expression of the virus can be silenced at the genetic level, the generation and replication of HBV can be blocked, thereby fundamentally reducing viral replication and infection of liver cells, it will undoubtedly be the most ideal treatment for hepatitis B. Small interfering nucleic acids, i.e. small interfering RNA or short interfering RNA (siRNA), can inhibit or block the expression of any target gene of interest (e.g., genes that cause diseases such as cancer) in a sequence-specific manner based on the mechanism of RNA interference (RNAi), thereby achieving the purpose of treating the disease.
[0003] RNA interference (RNAi) is a phenomenon in which double-stranded RNA (dsRNA) molecules shut down the expression of homologous genes or silence the expression of the gene at the mRNA level. RNA interference technology is also vividly called gene knock-down or gene silencing. It is a typical post-transcriptional gene regulation method, also known as post-transcriptional gene silencing (PTGS). The earliest report on RNA interference appeared in 1990, when two different research groups simultaneously reported the RNA interference phenomenon in transgenic plants. Later, RNA interference was observed in almost all eukaryotic organisms such as nematodes, fruit flies, zebrafish and mice. In 1999, Hamilton and Baulcombe detected RNA fragments with a length of 21-25 nucleotides in plants with RNA interference. These RNA fragments were proved to be necessary for RNA interference and were called small interfering nucleic acids (siRNA). Double-stranded siRNA forms an RNA-induced silencing complex (RISC) with cell-derived related enzymes and proteins. During RNA interference, the sense strand in the double-stranded siRNA is excluded from the complex, and the antisense strand guides RISC to bind to the homologous site of the target mRNA. The target mRNA is then degraded by ribonuclease III in the complex, thereby shutting down the expression of the target gene. Summary of the invention
[0004] The object of the present invention is to provide a novel double-stranded siRNA, its conjugate, its salt and their uses, and specifically to the use of the double-stranded siRNA and its conjugate of the present invention in the preparation of a drug for treating and / or preventing hepatitis B disease. In addition, the present invention also relates to a novel compound, and the use of the compound in the raw material for solid phase synthesis of DNA nucleotides, the synthetic raw material for siRNA drugs, the research of siRNA drugs, the research of gene function and / or the screening of the whole gene library, especially the use as the synthetic raw material for the double-stranded siRNA drug of the present invention. In addition, the present invention also relates to a novel nucleotide residue, and its use in the research of siRNA drugs, the research of gene function and / or the screening of the whole gene library, and the application as an oligonucleotide embedding group. The double-stranded siRNA and its conjugate of the present invention have higher gene expression inhibition activity and / or lower toxicity to HBV.
[0005] In one aspect, the present invention relates to a double-stranded siRNA, a conjugate thereof or a salt thereof, wherein the double-stranded siRNA comprises a sense strand and an antisense strand, and the double-stranded siRNA comprises one or more Y, wherein Y is Each nucleotide and Y in the double-stranded siRNA is independently modified or unmodified. Optionally, the Y can be at any position in the double-stranded siRNA.
[0006] In some embodiments of the double-stranded siRNA, its conjugate or salt thereof of the present invention, the double-stranded siRNA comprises 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10 Ys.
[0007] In some embodiments of the double-stranded siRNA, its conjugate or salt thereof of the present invention, the double-stranded siRNA comprises 1, 2, 3, 4 or 5 Ys.
[0008] In some embodiments of the double-stranded siRNA, its conjugate or salt thereof of the present invention, wherein the antisense strand comprises a sequence as shown in 5'-UGUGAAGCGAAGUGCACACUU-3' (SEQ ID NO: 40), or a sequence in which one or more nucleotide residues are replaced with Y in the sequence as shown in SEQ ID NO: 40; wherein each nucleotide and Y in the antisense strand are independently modified or unmodified, and the length of the antisense strand does not exceed 23 nucleotides, wherein Y has the meaning described in the present invention. Optionally, the Y replacement occurs at any position of the sequence as shown in SEQ ID NO: 40.
[0009] In some embodiments of the double-stranded siRNA, its conjugate or salt thereof of the present invention, wherein the sense strand comprises a sequence as shown in 5'-GUGUGCACUUCGCUUCACA-3' (SEQ ID NO: 20), or a sequence in which one or more nucleotide residues are replaced with Y in the sequence as shown in SEQ ID NO: 20, wherein each nucleotide and Y in the sense strand are independently modified or unmodified, and the length of the sense strand does not exceed 23 nucleotides. Optionally, the Y replacement occurs at any position of the sequence as shown in SEQ ID NO: 20.
[0010] In some embodiments of the double-stranded siRNA, its conjugate or salt thereof of the present invention, 70%, 75%, 80%, 85%, 90% or more of the nucleotides and Y in the sense strand or antisense strand of the double-stranded siRNA are modified.
[0011] In some embodiments of the double-stranded siRNA, its conjugate or salt thereof of the present invention, 70%, 75%, 80%, 85%, 90% or more of the nucleotides and Y in the sense strand and antisense strand of the double-stranded siRNA are modified.
[0012] In some embodiments of the double-stranded siRNA, its conjugate or salt thereof of the present invention, each nucleotide and Y in the double-stranded siRNA is modified.
[0013] In some embodiments of the double-stranded siRNA, its conjugate or its salt thereof of the present invention, the modification is selected from at least one of the following: 2'-methoxy modification, 2'-methoxyethyl modification, 2'-fluoro modification, thiophosphate linkage, 2'-deoxy modification, 2'-amino modification, locked nucleic acid modification, unlocked nucleic acid modification, ethylene glycol nucleic acid modification and 5'-vinyl phosphate modification.
[0014] In some embodiments of the double-stranded siRNA, its conjugate or its salt thereof of the present invention, the sense strand comprises a sequence in which 0, 1, 2, 3, 4 or 5 nucleotide residues are replaced by Y in the sequence as shown in SEQ ID NO: 20, wherein each nucleotide and Y in the sense strand are each independently modified or unmodified.
[0015] In some embodiments of the double-stranded siRNA, its conjugate or salt thereof of the present invention, the sense strand comprises a sequence in which one nucleotide residue is replaced by Y in the sequence as shown in SEQ ID NO: 20.
[0016] In some embodiments of the double-stranded siRNA, its conjugate or its salt of the present invention, wherein the antisense strand comprises a sequence in which 0, 1, 2, 3, 4 or 5 nucleotide residues are replaced by Y in the sequence as shown in SEQ ID NO: 40, wherein each nucleotide and Y of the antisense strand are independently modified or unmodified. In some embodiments of the double-stranded siRNA, its conjugate or its salt of the present invention, wherein the antisense strand comprises a sequence in which 1 nucleotide residue is replaced by Y in the sequence as shown in SEQ ID NO: 40.
[0017] In some embodiments of the double-stranded siRNA, its conjugate or its salt of the present invention, wherein the Y replacement occurs at position 1 to 19 of the 5' end of the sequence as shown in SEQ ID NO: 20 (i.e., the Y replacement optionally occurs at position 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18 or 19 of the 5' end of the sequence as shown in SEQ ID NO: 20).
[0018] In some embodiments of the double-stranded siRNA, its conjugate or its salt thereof of the present invention, wherein the Y replacement occurs at position 1 to 21 of the 5' end of the sequence as shown in SEQ ID NO: 40 (i.e., the Y replacement optionally occurs at position 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20 or 21 of the 5' end of the sequence as shown in SEQ ID NO: 40).
[0019] In some embodiments of the double-stranded siRNA, its conjugate or its salt of the present invention, wherein the sense strand comprises 5'-g●u●gu G c ACU A sequence in which 0, 1, 2, 3, 4 or 5 nucleotide residues are replaced by Y in the sequence shown in ucgcuucaca-3' (SEQ ID NO: 19), wherein each nucleotide and Y of the sense chain are independently modified or unmodified, and the Y replacement occurs at positions 1 to 19 of the 5' end of the sequence shown in SEQ ID NO: 19 (i.e., the Y replacement optionally occurs at positions 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18 or 19 of the 5' end of the sequence shown in SEQ ID NO: 19), and the length of the sense chain does not exceed 23 nucleotides.
[0020] In some embodiments of the double-stranded siRNA, its conjugate or salt of the present invention, wherein the antisense strand comprises 5'-u● G ●uga A g CG aagu G c A A sequence in which 0, 1, 2, 3, 4 or 5 nucleotide residues are replaced by Y in the sequence shown in cac●u●u-3' (SEQ ID NO: 36), wherein each nucleotide and Y of the antisense chain are independently modified or unmodified, and the Y replacement occurs at positions 1 to 21 of the 5' end of the antisense chain SEQ ID NO: 36 (i.e., the Y replacement optionally occurs at position 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18 or 19 of the 5' end of the sequence shown in SEQ ID NO: 36), and the length of the antisense chain does not exceed 23 nucleotides.
[0021] In some embodiments of the double-stranded siRNA, its conjugate or salt of the present invention, wherein the antisense strand is contained in 5'-u G ●uga(Agn)g CGaagu G c A A sequence in which 0, 1, 2, 3, 4 or 5 nucleotide residues are replaced by Y in the sequence shown in cac●u●u-3' (SEQ ID NO: 33), wherein each nucleotide and Y of the antisense strand are independently modified or unmodified, and the Y replacement occurs at positions 1 to 21 at the 5' end of the sequence shown in SEQ ID NO: 33 (i.e., the Y replacement optionally occurs at position 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18 or 19 at the 5' end of the sequence shown in SEQ ID NO: 33)), and the length of the antisense strand does not exceed 23 nucleotides.
[0022] Unless otherwise specified, in the context of the present invention, capital letters C, G, U, and A represent the base composition of natural nucleotides; lowercase letters c, g, u, and a represent that the ribose 2 position on the nucleotide represented by the corresponding capital letter is modified by methoxy; underscores under capital letters represent Indicates that the ribose 2 position on the nucleotide represented by the letter is modified by fluorine; Agn is adenosine-ethylene glycol nucleic acid; the spacer "●" indicates that the two nucleotide residues adjacent to the spacer "●" are connected by a thiophosphate group; Y is
[0023] In some embodiments of the double-stranded siRNA, its conjugate or salt of the present invention, the sense strand comprises one of the following nucleotide sequences:
[0024] SEQ ID NO:1, SEQ ID NO:2, SEQ ID NO:3, SEQ ID NO:4, SEQ ID NO:5, SEQ ID NO:6, SEQ ID NO:7, SEQ ID NO:8, SEQ ID NO:9, SEQ ID NO:10, SEQ ID NO:11, SEQ ID NO:12, SEQ ID NO:13, SEQ ID NO:14, SEQ ID NO:15, SEQ ID NO: 16, SEQ ID NO: 17, SEQ ID NO: 18, SEQ ID NO: 19 and SEQ ID NO: 21;
[0025] The sense strand has a length of no more than 23 nucleotides.
[0026] In some embodiments of the double-stranded siRNA, its conjugate or salt of the present invention, the antisense strand comprises one of the following nucleotide sequences:
[0028] SEQ ID NO:22, SEQ ID NO:23, SEQ ID NO:24, SEQ ID NO:25, SEQ ID NO:26, SEQ ID NO:27, SEQ ID NO:28, SEQ ID NO:29, SEQ ID NO:30, SEQ ID NO:31, SEQ ID NO:32, SEQ ID NO:33, SEQ ID NO:34, SEQ ID NO:35, SEQ ID NO:36, SEQ ID NO:37, SEQ ID NO:38 and SEQ ID NO:39;
[0029] The antisense strand is no longer than 23 nucleotides.
[0030] In some embodiments of the double-stranded siRNA, its conjugate or salt of the present invention, wherein the double-stranded siRNA comprises one of the following:
[0031] A sense strand having a nucleotide sequence as shown in SEQ ID NO: 15 and an antisense strand having a nucleotide sequence as shown in SEQ ID NO: 25, wherein the length of the sense strand and the antisense strand is each independently no more than 23 nucleotides;
[0032] A sense strand having a nucleotide sequence as shown in SEQ ID NO: 17 and an antisense strand having a nucleotide sequence as shown in SEQ ID NO: 25, wherein the length of the sense strand and the antisense strand is each independently no more than 23 nucleotides;
[0033] A sense strand having a nucleotide sequence as shown in SEQ ID NO: 15 and an antisense strand having a nucleotide sequence as shown in SEQ ID NO: 26, wherein the length of the sense strand and the antisense strand is each independently no more than 23 nucleotides;
[0034] A sense strand having a nucleotide sequence as shown in SEQ ID NO: 16 and an antisense strand having a nucleotide sequence as shown in SEQ ID NO: 26, wherein the length of the sense strand and the antisense strand is each independently no more than 23 nucleotides;
[0035] A sense strand having a nucleotide sequence as shown in SEQ ID NO: 17 and an antisense strand having a nucleotide sequence as shown in SEQ ID NO: 26, wherein the length of the sense strand and the antisense strand is each independently no more than 23 nucleotides;
[0036] A sense strand having a nucleotide sequence as shown in SEQ ID NO: 15 and an antisense strand having a nucleotide sequence as shown in SEQ ID NO: 27, wherein the length of the sense strand and the antisense strand is each independently no more than 23 nucleotides;
[0037] A sense strand comprising the nucleotide sequence shown in SEQ ID NO: 16 and an antisense strand comprising the nucleotide sequence shown in SEQ ID NO: 27, wherein the length of the sense strand and the antisense strand is each independently no more than 23 nucleotides;
[0038] A sense strand having a nucleotide sequence as shown in SEQ ID NO: 17 and an antisense strand having a nucleotide sequence as shown in SEQ ID NO: 27, wherein the length of the sense strand and the antisense strand is each independently no more than 23 nucleotides;
[0039] A sense strand comprising the nucleotide sequence shown in SEQ ID NO: 16 and an antisense strand comprising the nucleotide sequence shown in SEQ ID NO: 28, wherein the length of the sense strand and the antisense strand is each independently no more than 23 nucleotides;
[0040] A sense strand comprising the nucleotide sequence shown in SEQ ID NO: 17 and an antisense strand comprising the nucleotide sequence shown in SEQ ID NO: 28, wherein the length of the sense strand and the antisense strand is each independently no more than 23 nucleotides; or
[0041] A sense strand having a nucleotide sequence shown in SEQ ID NO: 18 and an antisense strand having a nucleotide sequence shown in SEQ ID NO: 28, wherein the length of the sense strand and the antisense strand is independently no more than 23 nucleotides.
[0042] In some embodiments of the double-stranded siRNA, its conjugate or its salt of the present invention, the double-stranded siRNA or its conjugate is selected from one of S1 to S143, S146, S147 and S150 in Table 1 of the present specification. In some embodiments of the double-stranded siRNA, its conjugate or its salt of the present invention, the double-stranded siRNA conjugate comprises the double-stranded siRNA and a conjugated group, that is, the double-stranded siRNA conjugate is a conjugate of the double-stranded siRNA and the conjugated group, wherein the conjugated group includes but is not limited to L-96 or DAW40007-4, and the structures of L-96 and DAW40007-4 are respectively:
[0043]
[0044] In some embodiments of the double-stranded siRNA, its conjugate or salt thereof of the present invention, the conjugated group is conjugated to the 3' end or the 5' end of the sense strand of the double-stranded siRNA.
[0045] In some embodiments of the double-stranded siRNA, its conjugate or salt thereof of the present invention, the conjugated group is conjugated to the 3' end of the sense strand of the double-stranded siRNA.
[0046] In some embodiments of the double-stranded siRNA, its conjugate or salt thereof of the present invention, the double-stranded siRNA is linked to the conjugated group through a phosphate group, a phosphorothioate group or a phosphate group.
[0047] On the other hand, the present invention also relates to a nucleotide residue Y, whose structure is:
[0048] On the other hand, the present invention also relates to a compound having a structure as shown in formula (I), or a stereoisomer, tautomer or acceptable salt of the compound as shown in formula (I),
[0049]
[0050] R 1 is methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl or tert-butyl, each of which is independently optionally substituted with 1, 2, 3 or 4 substituents selected from deuterium, hydroxyl, cyano, F, Cl, Br, I, methoxy, ethoxy, 1-propoxy and 2-propoxy;
[0051] Z and Y 1 are independently H, deuterium, a hydroxyl protecting group, HOC(═O)(CH 2 ) j C(=O)-, MC(=O)(CH 2 ) j C(═O)—, a phosphate group, a phosphorothioate group, a phosphoamido group, or a hydrogen phosphate group;
[0052] M is a solid support, preferably a hydroxyl- or amino-functionalized solid support, more preferably a resin or CPG, further preferably a macroporous resin or CPG, further preferably an aminomethyl resin, a hydroxyl resin or -NHCPG;
[0053] R is -NHR 2 or -N=CH-NR a R b ;
[0054] R 2 is an amino protecting group;
[0055] Each R a and R b are independently H or an amino protecting group, or R a , R b Together with the N atom to which they are attached, they form a heterocyclic group consisting of 5-6 ring atoms, wherein each heterocyclic group consisting of 5-6 ring atoms is independently optionally substituted by 1, 2, 3 or 4 substituents selected from deuterium, hydroxyl, cyano, F, Cl, Br, I, methyl, ethyl, n-propyl, isopropyl, methoxy, ethoxy, 1-propoxy and 2-propoxy;
[0056] wherein each j is independently 1, 2, 3, 4 or 5.
[0057] In some embodiments of the compounds described herein, Z and Y 1 each independently represents H, deuterium, benzyloxycarbonyl, 4-nitrobenzyloxycarbonyl, 4-bromobenzyloxycarbonyl, 4-methoxybenzyloxycarbonyl, biphenylmethoxycarbonyl, 2,2,2-trichloroethoxycarbonyl, 2-(trimethylsilyl)ethoxycarbonyl, allyloxycarbonyl, chloroacetyl, trifluoroacetyl, methoxyacetyl, phenoxyacetyl, benzoyl, 2,2,2-trichloroethyl, 2-trimethylsilylethyl, 1,1-dimethyl-2-propenyl, 3-methyl-3-butenyl, allyl, p-methoxybenzyldiphenylmethyl, tetrahydrofuranyl, methoxymethyl, methylthiomethyl, benzyloxymethyl, 2,2,2-trichloroethoxymethyl, 2-(trimethylsilyl)ethoxymethyl, methylsulfonyl, p-toluenesulfonyl, C 1-12 Alkyl, C 1-12 Alkyl C(=O)-, C 1-12 Alkylsilyl, C 6-10 Aryl C 1-6 Alkyl, HOC(=O)(CH 2 ) j C(=O)-, MC(=O)(CH 2 ) j C(=O)-, triphenylmethyl, MMTr, DMTr, 4',4',4'-trimethoxytrityl, Among them, j, M, X, R x , R y , R c and R d Has the meaning described in the present invention.
[0058] In some embodiments of the compounds described herein, Z and Y 1each independently represents H, deuterium, benzyloxycarbonyl, 4-nitrobenzyloxycarbonyl, 4-bromobenzyloxycarbonyl, 4-methoxybenzyloxycarbonyl, biphenylmethoxycarbonyl, 2,2,2-trichloroethoxycarbonyl, 2-(trimethylsilyl)ethoxycarbonyl, allyloxycarbonyl, chloroacetyl, trifluoroacetyl, methoxyacetyl, phenoxyacetyl, benzoyl, 2,2,2-trichloroethyl, 2-trimethylsilylethyl, 1,1-dimethyl-2-propenyl, 3-methyl-3-butenyl, allyl, p-methoxybenzyldiphenylmethyl, tetrahydrofuranyl, methoxymethyl, methylthiomethyl, benzyloxymethyl, 2,2,2-trichloroethoxymethyl, 2-(trimethylsilyl)ethoxymethyl, methylsulfonyl, p-toluenesulfonyl, C 1-10 Alkyl, C 1-10 Alkyl C(=O)-, C 1-10 Alkylsilyl, C 6-10 Aryl C 1-4 Alkyl, HOC(=O)(CH 2 ) j C(=O)-, MC(=O)(CH 2 ) j C(=O)-, triphenylmethyl, MMTr, DMTr, 4',4',4'-trimethoxytrityl, Among them, j, M, X, R x , R y , R c and R d Has the meaning described in the present invention.
[0059] In some embodiments of the compounds described herein, Z and Y 1 each independently represents H, deuterium, benzyloxycarbonyl, 4-nitrobenzyloxycarbonyl, 4-bromobenzyloxycarbonyl, 4-methoxybenzyloxycarbonyl, biphenylmethoxycarbonyl, 2,2,2-trichloroethoxycarbonyl, 2-(trimethylsilyl)ethoxycarbonyl, allyloxycarbonyl, chloroacetyl, trifluoroacetyl, methoxyacetyl, phenoxyacetyl, benzoyl, 2,2,2-trichloroethyl, 2-trimethylsilylethyl, 1,1-dimethyl-2-propenyl, 3-methyl-3-butenyl, allyl, p-methoxybenzyldiphenylmethyl, tetrahydrofuranyl, methoxymethyl, methylthiomethyl, benzyloxymethyl, 2,2,2-trichloroethoxymethyl, 2-(trimethylsilyl)ethoxymethyl, methylsulfonyl, p-toluenesulfonyl, C 1-8 Alkyl, C 1-8 Alkyl C(=O)-, C 1-8 Alkylsilyl, phenyl C 1-3 Alkyl, HOC(=O)(CH 2 ) jC(=O)-, MC(=O)(CH 2 ) j C(=O)-, triphenylmethyl, MMTr, DMTr, 4',4',4'-trimethoxytrityl, Among them, j, M, X, R x , R y , R c and R d Has the meaning described in the present invention.
[0060] In some embodiments of the compounds described herein, Z and Y 1 each independently represents H, deuterium, benzyloxycarbonyl, 4-nitrobenzyloxycarbonyl, 4-bromobenzyloxycarbonyl, 4-methoxybenzyloxycarbonyl, biphenylmethoxycarbonyl, 2,2,2-trichloroethoxycarbonyl, 2-(trimethylsilyl)ethoxycarbonyl, allyloxycarbonyl, chloroacetyl, trifluoroacetyl, methoxyacetyl, phenoxyacetyl, benzoyl, 2,2,2-trichloroethyl, 2-trimethylsilylethyl, 1,1-dimethyl-2-propenyl, 3-methyl-3-butenyl, allyl, p-methoxybenzyldiphenylmethyl, tetrahydrofuranyl, methoxymethyl, methylthiomethyl, benzyloxymethyl, 2,2,2-trichloroethoxymethyl, 2-(trimethylsilyl)ethoxymethyl, methylsulfonyl, p-toluenesulfonyl, C 1-6 Alkyl, C 1-6 Alkyl C(=O)-, C 1-6 Alkylsilyl, benzyl, phenethyl, HOC(=O)(CH 2 ) j C(=O)-, MC(=O)(CH 2 ) j C(=O)-, triphenylmethyl, MMTr, DMTr, 4',4',4'-trimethoxytrityl, Among them, j, M, X, R x , R y , R c and R d Has the meaning described in the present invention.
[0061] In some embodiments of the compounds described herein, X is Cl or Br.
[0062] In some embodiments of the compounds described herein, each R x and R y is independently a hydroxy protecting group.
[0063] In some embodiments of the compounds described herein, each R c and R d are independently H or an amino protecting group; or Rc , R d Together with the N atom to which they are attached, they form a heterocyclic group consisting of 5-6 ring atoms, and the heterocyclic group consisting of 5-6 ring atoms is independently optionally substituted by 1, 2, 3 or 4 substituents selected from deuterium, hydroxyl, cyano, F, Cl, Br, I, methyl, ethyl, propyl, methoxy, ethoxy, 1-propoxy and 2-propoxy.
[0064] In some embodiments of the compounds described herein, R 2 is 9-fluorenylmethoxycarbonyl, benzyloxycarbonyl, 4-nitrobenzyloxycarbonyl, 4-bromobenzyloxycarbonyl, 4-methoxybenzyloxycarbonyl, biphenylmethoxycarbonyl, 2,2,2-trichloroethoxycarbonyl, 2-(trimethylsilyl)ethoxycarbonyl, allyloxycarbonyl, chloroacetyl, trifluoroacetyl, methoxyacetyl, phenoxyacetyl, benzoyl, methyl, tert-butyl, 2-trimethylsilylethyl, 1,1-dimethyl-2-propenyl, 3-methyl-3-butenyl, allyl, benzyl, p-methoxybenzyldiphenylmethyl, trityl, tetrahydrofuranyl, methoxymethyl, methylthiomethyl, benzyloxymethyl, 2,2,2-trichloroethoxymethyl, 2-(trimethylsilyl)ethoxymethyl, methylsulfonyl, p-toluenesulfonyl, trimethylsilyl, triethylsilyl, triisopropylsilyl, C 1-6 Alkoxy or R 3 C(=O)-, where R 3 Has the meaning described in the present invention.
[0065] In some embodiments of the compounds described herein, each R a and R b are independently H, methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, tert-butyl, methoxy, ethoxy, 1-propoxy, 2-propoxy, 9-fluorenylmethoxycarbonyl, benzyloxycarbonyl, 4-nitrobenzyloxycarbonyl, 4-bromobenzyloxycarbonyl, 4-methoxybenzyloxycarbonyl, biphenylmethoxycarbonyl, 2,2,2-trichloroethoxycarbonyl, 2-(trimethylsilyl)ethoxycarbonyl, allyloxycarbonyl, chloroacetyl, trifluoroacetyl, methoxyacetyl, phenoxyacetyl, benzoyl, 2-trimethylsilylethyl, 1,1-dimethyl-2-propenyl, 3-methyl-3-butenyl, allyl, benzyl, p-methoxybenzyldiphenylmethyl, trityl, tetrahydrofuranyl, methoxymethyl, methylthiomethyl, benzyloxymethyl, 2,2,2-trichloroethoxymethyl, 2-(trimethylsilyl)ethoxymethyl, methanesulfonyl, p-toluenesulfonyl, trimethylsilyl, triethylsilyl, triisopropylsilyl or R 4 C(=O)-, or R a , R bTogether with the N atom to which they are attached, they form a pyrrolidinyl, morpholinyl, piperidinyl or piperazinyl group, wherein the pyrrolidinyl, morpholinyl, piperidinyl and piperazinyl groups are each independently optionally substituted with 1, 2, 3 or 4 substituents selected from deuterium, hydroxyl, cyano, F, Cl, Br, I, methoxy, ethoxy, 1-propoxy and 2-propoxy groups, wherein R 4 Has the meaning described in the present invention.
[0066] In some embodiments of the compounds described herein, each R 3 and R 4 Independently for C 1-6 Alkyl, halogenated C 1-6 Alkyl, C 1-6 Alkoxy, phenyl, halogen-substituted phenyl, C 1-6 Alkylphenyl or benzyl.
[0067] In some embodiments of the compounds described herein, each R 3 and R 4 Independently for C 1-4 Alkyl, halogenated C 1-4 Alkyl, C 1-4 Alkoxy, phenyl, halogen-substituted phenyl, C 1-4 Alkylphenyl or benzyl.
[0068] In some embodiments of the compounds described herein, each R 3 and R 4 are independently methyl, ethyl, n-propyl, isopropyl, trifluoromethyl, difluoromethyl, monofluoromethyl, trichloromethyl, dichloromethyl, monochloromethyl, 2,2,2-trichloroethyl, methoxy, ethoxy, 1-propoxy, 2-propoxy, 1-butoxy, 2-methyl-1-propoxy, 2-butoxy, tert-butoxy, phenyl, halogen-substituted phenyl, C 1-3 Alkylphenyl or benzyl.
[0069] In some embodiments of the compounds described herein, each R x and R yare independently benzyloxycarbonyl, 4-nitrobenzyloxycarbonyl, 4-bromobenzyloxycarbonyl, 4-methoxybenzyloxycarbonyl, biphenylmethoxycarbonyl, 2,2,2-trichloroethoxycarbonyl, 2-(trimethylsilyl)ethoxycarbonyl, allyloxycarbonyl, chloroacetyl, trifluoroacetyl, methoxyacetyl, phenoxyacetyl, benzoyl, 2,2,2-trichloroethyl, 2-trimethylsilylethyl, 1,1-dimethyl-2-propenyl, 3-methyl-3-butenyl, allyl, p-methoxybenzyldiphenylmethyl, tetrahydrofuranyl, methoxymethyl, methylthiomethyl, benzyloxymethyl, 2,2,2-trichloroethoxymethyl, 2-(trimethylsilyl)ethoxymethyl, methylsulfonyl, p-toluenesulfonyl, cyano C 1-6 Alkyl, C 1-6 Alkyl, C 1-6 Alkyl C(=O)-, C 1-6 alkylsilyl, phenyl, halogen-substituted phenyl, benzyl or phenethyl.
[0070] In some embodiments of the compounds described herein, each R x and R y are independently benzyloxycarbonyl, 4-nitrobenzyloxycarbonyl, 4-bromobenzyloxycarbonyl, 4-methoxybenzyloxycarbonyl, biphenylmethoxycarbonyl, 2,2,2-trichloroethoxycarbonyl, 2-(trimethylsilyl)ethoxycarbonyl, allyloxycarbonyl, chloroacetyl, trifluoroacetyl, methoxyacetyl, phenoxyacetyl, benzoyl, 2,2,2-trichloroethyl, 2-trimethylsilylethyl, 1,1-dimethyl-2-propenyl, 3-methyl-3-butenyl, allyl, p-methoxybenzyldiphenylmethyl, tetrahydrofuranyl, methoxymethyl, methylthiomethyl, benzyloxymethyl, 2,2,2-trichloroethoxymethyl, 2-(trimethylsilyl)ethoxymethyl, methanesulfonyl, p-toluenesulfonyl, CNCH 2 -、CN(CH 2 ) 2 -、CNCH(CH 3 ) 2 CH 2 -、CN(CH 2 ) 3 -、CNCH(CH 3 ) 2 CH 2 CH 2 -, methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, tert-butyl, C 1-4 Alkyl C(=O)-, C 1-4 alkylsilyl, phenyl, halogen-substituted phenyl, benzyl or phenethyl.
[0071] In some embodiments of the compounds described herein, each Rc and R d are independently methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, tert-butyl, methoxy, ethoxy, 1-propoxy, 2-propoxy, 9-fluorenylmethoxycarbonyl, benzyloxycarbonyl, 4-nitrobenzyloxycarbonyl, 4-bromobenzyloxycarbonyl, 4-methoxybenzyloxycarbonyl, biphenylmethoxycarbonyl, 2,2,2-trichloroethoxycarbonyl, 2-(trimethylsilyl)ethoxycarbonyl, allyloxycarbonyl, chloroacetyl, trifluoroacetyl, methoxyacetyl, phenoxy acetyl, benzoyl, 2-trimethylsilylethyl, 1,1-dimethyl-2-propenyl, 3-methyl-3-butenyl, allyl, benzyl, p-methoxybenzyldiphenylmethyl, trityl, tetrahydrofuranyl, methoxymethyl, methylthiomethyl, benzyloxymethyl, 2,2,2-trichloroethoxymethyl, 2-(trimethylsilyl)ethoxymethyl, methanesulfonyl, p-toluenesulfonyl, trimethylsilyl, triethylsilyl, triisopropylsilyl or R 4 C(=O)-, or R c , R d Together with the N atom to which they are attached, they form a pyrrolidinyl, morpholinyl, piperidinyl or piperazinyl group, each of which is independently optionally substituted with 1, 2, 3 or 4 substituents selected from deuterium, hydroxyl, cyano, F, Cl, Br, I, methoxy, ethoxy, 1-propoxy and 2-propoxy.
[0072] In some embodiments of the compounds of the present invention, the compounds of the present invention have a structure as shown in formula (II),
[0073]
[0074] In another aspect of the present invention, the present invention also relates to a pharmaceutical composition, which comprises the double-stranded siRNA, its conjugate or salt thereof according to the present invention, and a pharmaceutically acceptable carrier.
[0075] In another aspect of the present invention, the present invention also relates to the use of the double-stranded siRNA conjugate, its conjugate and the pharmaceutical composition of the present invention in the preparation of drugs for treating and / or preventing hepatitis B disease.
[0076] In another aspect of the present invention, the present invention also relates to the use of the nucleotide residues of the present invention as drugs for siRNA research, gene function research and / or screening of a whole gene library, wherein the structure of the nucleotide residues is:
[0077] In some embodiments of the application of the nucleotide residues described in the present invention, the siRNA drug is the double-stranded siRNA drug described in the present invention.
[0078] In another aspect of the present invention, the present invention also relates to the use of the compounds described in the present invention in raw materials for solid phase synthesis of DNA nucleotides, raw materials for synthesis of oligonucleotide drugs, raw materials for synthesis of siRNA drugs, siRNA drug research, gene function research and / or screening of whole gene libraries.
[0079] In another aspect of the present invention, the present invention also relates to the use of the nucleotide residues of the present invention as oligonucleotide intercalating groups, wherein the oligonucleotide is a nucleotide sequence containing 10 to 50 nucleotides or nucleotide base pairs, and the oligonucleotide can inhibit or block the expression of a gene, and the structure of the nucleotide residues is:
[0080] In some embodiments of the present invention, the nucleotide residues are used as oligonucleotide embedding groups, wherein the gene is the HBV gene.
[0081] In some embodiments of the present invention, the nucleotide residues are used as oligonucleotide intercalating groups, wherein the oligonucleotide is siRNA.
[0082] In some embodiments of the present invention where the nucleotide residues are used as oligonucleotide intercalating groups, the siRNA comprises a sense strand and an antisense strand.
[0083] In some embodiments of the present invention, the nucleotide residues are used as oligonucleotide intercalating groups, wherein the nucleotide residues are only intercalated into the positive strand of the siRNA.
[0084] In some embodiments of the present invention, the nucleotide residues are used as oligonucleotide intercalating groups, wherein the nucleotide residues are only intercalated into the antisense strand of the siRNA.
[0085] In some embodiments of the present invention, the nucleotide residues are used as oligonucleotide intercalating groups, wherein the nucleotide residues are intercalated into the sense strand and the antisense strand of the siRNA.
[0086] In some embodiments of the present invention where the nucleotide residues are used as oligonucleotide intercalating groups, the sense strand of the siRNA comprises a sequence as shown in SEQ ID NO:19.
[0087] In some embodiments of the present invention in which the nucleotide residues are used as oligonucleotide intercalating groups, the antisense strand of the siRNA comprises a sequence as shown in SEQ ID NO:36 or SEQ ID NO:33.
[0088] Detailed description of the invention
[0089] Definitions and general terms
[0090] In the present invention, the terms "comprise" or "include" are open expressions, that is, including the contents specified in the present invention, but not excluding other contents.
[0091] In the present invention, the term "small interfering RNA (siRNA)" is a type of double-stranded RNA molecule with a length of 17 to 30 nucleotides, comprising a sense strand and an antisense strand. siRNA mediates the targeted cleavage of RNA transcripts in the RISC pathway by forming a silencing complex (RISC). Specifically, siRNA guides the specific degradation of mRNA sequences through the known RNA interference (RNAi) process, inhibiting the translation of mRNA into amino acids and proteins. For example, siRNA can regulate (e.g., inhibit) the expression of hepatitis B virus in cells.
[0092] In the present invention, the term "antisense strand (or guide strand)" refers to a siRNA strand that includes a region that is substantially complementary to a target sequence (such as a sequence in the mRNA of hepatitis B virus). "Sense strand (or follower strand)" refers to a siRNA strand that contains a region that is substantially complementary to the antisense strand. The antisense strand or sense strand in the double-stranded siRNA of the present invention contains one or more (e.g., 2, 3, 4 or 5) nucleotide residues Y, and the Y has the structure described in the present invention.
[0093] The term "substantially complementary" refers to complete complementarity or at least partial complementarity, for example, the antisense strand is completely complementary or at least partially complementary to the target sequence. In the case of partial complementarity, mismatches can exist in the interior or terminal regions of the molecule, wherein the most tolerated mismatches exist in the terminal regions, for example, within 5, 4, 3 or 2 nucleotides of the 5'- and / or 3'-end of either strand of the siRNA.
[0094] It should be noted that "at least part of the antisense strand is substantially complementary to the mRNA" means that the antisense strand has a polynucleotide that is substantially complementary to a continuous portion of the mRNA of interest (e.g., the mRNA encoding the hepatitis B virus). Alternatively, if a polynucleotide is substantially non-interruptedly complementary to a portion of the mRNA encoding the hepatitis B virus, the antisense strand is complementary to at least a portion of the mRNA of the hepatitis B virus.
[0095] In the present invention, the term "target sequence" refers to a continuous portion of the nucleotide sequence of an mRNA molecule formed during transcription of a gene encoding hepatitis B virus, including mRNA that is an RNA processing product of a primary transcription product.
[0096] In the present disclosure, a double-stranded siRNA analog refers to a complex of a ribonucleic acid molecule having a double-stranded structure, comprising two antiparallel and substantially complementary nucleic acid chains, which have "sense" and "antisense" orientations relative to the target RNA. In the present disclosure, "complementary" has a meaning well known to those skilled in the art, that is, in a double-stranded nucleic acid molecule, the bases of one chain are paired with the bases on the other chain in a complementary manner. The purine base adenine (A) is always paired with the pyrimidine base uracil (U); the purine base guanine (G) is always paired with the pyrimidine base cytosine (C). Each base pair includes a purine and a pyrimidine. When adenine on one chain is always paired with uracil on the other chain, and guanine is always paired with cytosine, the two chains are considered to be complementary to each other, and the sequence of the chain can be inferred from the sequence of its complementary chain.
[0097] In the present invention, the term "inhibiting the expression of hepatitis B virus genes" includes any level of inhibition of hepatitis B virus (abbreviated as HBV) genes, for example, at least partial inhibition of hepatitis B virus gene expression, such as inhibition of at least about 20%, at least about 25%, at least about 30%, at least about 35%, at least about 40%, at least about 45%, at least about 50%, at least about 55%, at least about 60%, at least about 65%, at least about 70%, at least about 75%, at least about 80%, at least about 85%, at least about 90%, at least about 91%, at least about 92%, at least about 93%, at least about 94%, at least about 95%, at least about 96%, at least about 97%, at least about 98% or at least about 99%. Wherein, the expression of hepatitis B virus genes can be evaluated based on the level of any variable related to the expression of hepatitis B virus genes, for example, the mRNA level of hepatitis B virus or the level of hepatitis B virus protein. Inhibition can be evaluated by a reduction in the absolute or relative level of one or more of these variables compared to a control level. A control level can be any type of control level utilized in the art, e.g., a baseline level before administration, or a level measured from a similar subject, cell or sample that has never been treated or treated with a control (e.g., a control with only a buffer or a control without an active agent).
[0098] In the present invention, "pharmaceutical composition" may refer to a composition used for the treatment of a disease, and may also be used for in vitro cell culture experiments. When used for the treatment of a disease, the term "pharmaceutical composition" generally refers to a unit dosage form, and may be prepared by any of the methods well known in the pharmaceutical field. All methods include the step of combining the active ingredient with an excipient that constitutes one or more accessory ingredients. Typically, the composition is prepared by uniformly and fully combining active double-stranded siRNA with a liquid excipient, a finely divided solid excipient, or both.
[0099] The siRNA of the present invention contains a nucleotide group as a basic structural unit. It is well known to those skilled in the art that the nucleotide group contains a phosphate group, a ribose group and a base, which will not be repeated here. Each nucleotide in the siRNA is independently a modified or unmodified nucleotide, preferably an unmodified nucleotide. The double-stranded siRNA of the present invention contains a sense strand and an antisense strand.
[0100] The term "intercalation" as used herein means that an intercalation group is linked to at least one nucleotide residue in the sequence, including replacing a nucleotide residue in the sequence with an intercalation group (such as Y).
[0101] The "intercalating group" described in the present invention is a residue of an analog of a natural nucleotide base, which is different from any natural nucleotide base disclosed in any patent. After being introduced into a nucleic acid sequence, it can make the sequence have certain functions (such as bringing unexpected activities). As described in the present invention, Y, after being embedded in an oligonucleotide sequence as an intercalating group, can inhibit gene expression and thus produce unexpected activities.
[0102] The "oligonucleotide intercalating group" of the present invention refers to the intercalating group connected to at least one nucleotide residue in the oligonucleotide, including replacing a nucleotide residue in the oligonucleotide with an intercalating group (such as Y).
[0103] The Y-embedded sequence of the present invention refers to a sequence in which at least one nucleotide residue is connected to Y, including a sequence in which a nucleotide residue is replaced by Y in the sequence. The Y-embedded sequence of the present invention may also be optionally modified, such as methoxy modification, fluorine modification, and thiophosphate linkage. The Y-embedded sequence of the present invention includes, but is not limited to, Y-embedded siRNA, Y-embedded sense strand, and Y-embedded antisense strand.
[0104] The conjugated groups of the present invention include pharmaceutically acceptable conjugated groups. Generally speaking, pharmaceutically acceptable conjugated groups include pharmaceutically acceptable targeting molecules and optional linkers. For exemplary conjugated groups, linkers, and targeting molecules, see the disclosures of WO2015006740A2 and CN114555188A. Exemplary conjugated groups include, but are not limited to, L96, NAG37, or DAW40007-4 described in the present invention.
[0105] Unless otherwise specified, "conjugation" refers to the covalent linkage of two or more chemical moieties, each with a specific function, to each other; accordingly, "conjugate" refers to a compound formed by covalent linkage of the chemical moieties.
[0106] The double-stranded siRNA conjugate of the present invention is a compound formed by connecting the double-stranded siRNA and a pharmaceutically acceptable conjugation group, and the double-stranded siRNA and the pharmaceutically acceptable conjugation group are covalently linked.
[0107] In the present invention, the term "pharmaceutically acceptable" means that the substance or composition must be chemically and / or toxicologically compatible with the other ingredients of the formulation and / or the mammals treated therewith. Preferably, the "pharmaceutically acceptable" of the present invention refers to those approved by federal regulatory agencies or national governments or listed in the United States Pharmacopoeia or other generally recognized pharmacopeias for use in animals, especially humans.
[0108] In the present invention, the term "pharmaceutically acceptable excipient" may include any solvent, solid excipient, diluent or other liquid excipient, etc., suitable for a specific target dosage form. Except for any conventional excipients that are incompatible with the double-stranded siRNA or its conjugate or its salt of the present invention, such as any adverse biological effects produced or interactions with any other components of the pharmaceutically acceptable composition in a harmful manner, their use is also within the scope of the present invention.
[0109] As used herein, the term "treatment" refers to the use of drugs to obtain the desired pharmacological and / or physiological effects. The effect may be preventive in terms of completely or partially preventing a disease or its symptoms, and / or may be therapeutic in terms of partially or completely curing a disease and / or the adverse effects caused by the disease. "Treatment" as used herein covers diseases in mammals, particularly humans, and includes: (a) preventing the occurrence of a disease or condition in an individual who is susceptible to the disease but has not yet been diagnosed with the disease; (b) inhibiting the disease, such as blocking the development of the disease; or (c) alleviating the disease, such as alleviating symptoms associated with the disease. "Treatment" as used herein covers any medication that administers a drug, RNAi agent or siRNA to an individual to treat, cure, alleviate, improve, reduce or inhibit an individual's disease, including but not limited to administering a drug containing an RNAi agent, siRNA or siRNA conjugate described herein to an individual in need.
[0110] Unless otherwise specified, in the context of the present invention, capital letters C, G, U, and A represent the base composition of natural nucleotides; lowercase letters c, g, u, and a represent that the ribose 2 position on the nucleotide represented by the corresponding capital letter is modified by methoxy; underscores under capital letters represent Indicates that the ribose 2 position on the nucleotide represented by the letter is modified by fluorine; the spacer "●" indicates that the two nucleotide residues adjacent to the spacer "●" are phosphorothioate groups. If there is no "●" between nucleotide residues, it means that the nucleotide residues are linked by phosphate groups. For example, "g●u" means that the g and u residues are linked by a thiophosphate group, "gu" means that the g and u residues are linked by a phosphate group; Agn is adenosine-glycol nucleic acid (Glycol nucleic acid, GNA, ); Y in double-stranded siRNA represents Wherein, the ribose position 2 modified by fluorine in the present invention means that the hydroxyl group at the ribose position 2 is replaced by F; the ribose position 2 modified by methoxy means that the hydroxyl group at the ribose position 2 is replaced by methoxy.
[0111] In the context of the present invention, Bz stands for benzoyl; MMTr stands for 4'-methoxytrityl; DMTr stands for 4',4'-dimethoxytriphenylmethyl.
[0112] In the present invention, "phosphate group", "phosphate group" and "phosphate bond" are used interchangeably, including monophosphate group, phosphodiester group or phosphotriester group. The "phosphate group" in "phosphorothioate group" also has the same meaning. Unless otherwise specified, the phosphate group between natural nucleotides is a phosphodiester group. Unless otherwise specified, the sequence in which Y replaces one or more nucleotide residues in the present invention means that 1 Y replaces 1 nucleotide residue, rather than 1 Y replaces 2 or more nucleotide residues. If 2 nucleotide residues are replaced, it should be that 2 Ys replace 2 nucleotide residues respectively. For example, the antisense strand contains a sequence in which 0, 1, 2, 3, 4 or 5 nucleotide residues are replaced by Y in the sequence shown in SEQ ID NO: 40, which should mean that the antisense strand contains a sequence in which 0, 1, 2, 3, 4 or 5 Ys are replaced by 0, 1, 2, 3, 4 or 5 nucleotide residues respectively in the sequence shown in SEQ ID NO: 40.
[0113] The term "oxo" refers to a =0 group. For example, a carbon atom is connected to an oxygen atom via a double bond, wherein a ketone or an aldehyde is formed.
[0114] As used herein, "chemically modified" or "modification" means a structure that is chemically different when compared to a naturally occurring counterpart, including all changes by chemical means, such as the addition or removal of a chemical moiety, or the substitution of one chemical moiety for another.
[0115] The compounds of the present invention may be asymmetric, for example, having one or more stereoisomers. Unless otherwise indicated, all stereoisomers are included, such as enantiomers and diastereomers. The compounds of the present invention containing asymmetric carbon atoms can be isolated in optically pure forms or racemic forms. Optically pure forms can be resolved from racemic mixtures or synthesized by using chiral starting materials or chiral reagents.
[0116] Optically active (R)- and (S)-isomers, as well as D and L isomers, can be prepared by chiral synthesis or chiral reagents or other conventional techniques. If one enantiomer of a compound of the invention is desired, it can be prepared by asymmetric synthesis or derivatization with a chiral auxiliary, wherein the resulting diastereomeric mixture is separated and the auxiliary group is cleaved to provide the pure desired enantiomer. Alternatively, when the molecule contains a basic functional group (such as an amino group) or an acidic functional group (such as a carboxyl group), diastereomeric salts are formed with an appropriate optically active acid or base, followed by diastereomeric resolution by conventional methods known in the art, and then the pure enantiomer is recovered. In addition, separation of enantiomers and diastereomers is usually accomplished by using chromatography, which employs a chiral stationary phase and is optionally combined with chemical derivatization (e.g., carbamate formation from an amine).
[0117] The present invention also includes isotopically labeled compounds of the present invention which are identical to those described herein, but in which one or more atoms are replaced by an atom having an atomic mass or mass number different from the atomic mass or mass number usually found in nature. Examples of isotopes that may be incorporated into compounds of the present invention include isotopes of hydrogen, carbon, nitrogen, oxygen, phosphorus, sulfur, fluorine, iodine, and chlorine, such as 2 H. 3 H. 11 C, 13C, 14 C. 13 N. 15 N. 15 O. 17 O. 18 O. 31 P. 32 P. 35 S. 18 F. 123 I. 125 I and 36 Cl et al.
[0118] Unless otherwise indicated, when a position is specifically designated as deuterium (D), the position is understood to have deuterium (i.e., at least 10% deuterium incorporation) at least 1000 times greater than the natural abundance of deuterium (which is 0.015%). The natural abundance of the compound in the example may be at least 1000 times greater than deuterium, at least 2000 times greater than deuterium, at least 3000 times greater than deuterium, at least 4000 times greater than deuterium, at least 5000 times greater than deuterium, at least 6000 times greater than deuterium or more. The present invention also includes various deuterated forms of the formula (I) compound. Each available hydrogen atom connected to a carbon atom may be independently replaced by a deuterium atom. Those skilled in the art can synthesize deuterated forms of the formula (I) compound with reference to the relevant literature. In preparing the deuterated form of the compound of formula (I), commercially available deuterated starting materials may be used, or they may be synthesized using conventional techniques using deuterated reagents, including but not limited to deuterated borane, trideuterated borane in tetrahydrofuran, deuterated lithium aluminum hydride, deuterated iodoethane and deuterated iodomethane.
[0119] The conjugated groups of the present invention can enhance the delivery of therapeutic agents to specific target locations (e.g., specific organs or tissues) in objects such as humans or animals. In some embodiments of the present invention, the conjugated groups can enhance the targeted delivery of expression-inhibiting double-stranded siRNA. In some embodiments of the present invention, the conjugated groups can enhance the delivery of expression-inhibiting double-stranded siRNA to the liver.
[0120] The conjugated groups of the present invention can be directly or indirectly connected to a compound, such as a therapeutic agent, for example, an expression inhibitory oligonucleotide, for example, the 3' or 5' end of an expression inhibitory oligonucleotide. In some embodiments of the present invention, the expression inhibitory oligonucleotide includes one or more modified nucleotides. In some embodiments of the present invention, the expression inhibitory oligonucleotide is an RNAi agent, such as a double-stranded siRNA agent comprising a sense strand and an antisense strand. In some embodiments of the present invention, the conjugated groups disclosed in the present invention are connected to the 3' end of the sense strand of the double-stranded siRNA agent. In some embodiments, the conjugated groups disclosed in the present invention are connected to the expression inhibitory oligonucleotide agent at the 3' end of the sense strand of the double-stranded siRNA agent via a phosphate, a thiophosphate or a phosphonate group.
[0121] The definitions and conventions of stereochemistry used in this invention are generally based on the following references: SP Parker, Ed., McGraw-Hill Dictionary of Chemical Terms (1984) McGraw-Hill Book Company, New York; and Eliel, E. and Wilen, S., "Stereochemistry of Organic Compounds", John Wiley & Sons, Inc., New York, 1994. The compounds of the present invention may contain asymmetric centers or chiral centers and therefore exist in different stereoisomers. All stereoisomeric forms of the compounds of the present invention, including but not limited to diastereomers, enantiomers, atropisomers, and mixtures thereof, such as racemic mixtures, constitute a part of the present invention. Many organic compounds exist in optically active forms, that is, they have the ability to rotate the plane of plane polarized light. When describing optically active compounds, the prefixes D, L or R, S are used to indicate the absolute configuration of the chiral center of the molecule. The prefixes d, l or (+), (-) are used to name the sign of rotation of plane polarized light of a compound. (-) or l means that the compound is levorotatory, and the prefix (+) or d means that the compound is dextrorotatory. The chemical structures of these stereoisomers are identical, but their stereostructures are different. Specific stereoisomers can be enantiomers, and a mixture of isomers is often called an enantiomeric mixture. A 50:50 mixture of enantiomers is called a racemic mixture or racemate, which may result in no stereoselectivity or stereospecificity during chemical reactions. The terms "racemic mixture" and "racemate" refer to an equimolar mixture of two enantiomers that lacks optical activity.
[0122] The term "tautomer" or "tautomeric form" refers to structural isomers of different energies that can be interconverted via a low energy barrier. For example, proton tautomers (i.e., prototropic tautomers) include interconversions via proton migration, such as keto-enol and imine-enamine isomerizations.
[0123] The term "composition" refers to a mixture of a drug and other chemical components containing one or more compounds described herein or their physiologically pharmaceutically acceptable salts or precursors, as well as other components such as physiologically pharmaceutically acceptable carriers and excipients. The purpose of the composition is to facilitate administration to an organism, facilitate the absorption of the active ingredients, and thus exert biological activity.
[0124] The term "pharmaceutically acceptable excipient" or "pharmaceutically acceptable excipient" includes, but is not limited to, any adjuvant, carrier, excipient, glidant, sweetener, diluent, preservative, dye / colorant, flavoring agent, surfactant, wetting agent, dispersant, suspending agent, stabilizer, isotonic agent, solvent or emulsifier approved by the U.S. Food and Drug Administration for use in humans or domestic animals.
[0125] Unless otherwise specified, the "compound", "ligand", "nucleic acid conjugate", "double-stranded siRNA conjugate", "double-stranded siRNA", and "nucleic acid" of the present invention may independently exist in the form of a salt, a mixed salt, or a non-salt (e.g., a free acid or a free base). When it exists in the form of a salt or a mixed salt, it may be a pharmaceutically acceptable salt.
[0126] The term "acceptable salt" includes acceptable acid addition salts and pharmaceutically acceptable base addition salts. "Acceptable acid addition salt" refers to salts formed with inorganic or organic acids that can retain the biological effectiveness of free bases without other side effects. Inorganic acid salts include, but are not limited to, hydrochlorides, hydrobromides, sulfates, nitrates, phosphates, etc.; organic acid salts include, but are not limited to, formates, acetates, 2,2-dichloroacetates, trifluoroacetates, propionates, caproates, caprylates, decanoates, undecylenates, glycolates, gluconates, lactates, sebacates, adipates, glutarates, malonates, oxalates, maleates, succinates, fumarates, tartrates, citrates, palmitates, stearates, oleates, cinnamates, laurates, malates, glutamates, pyroglutamates, aspartates, benzoates, methanesulfonates, benzenesulfonates, p-toluenesulfonates, alginate, ascorbates, salicylates, 4-aminosalicylates, naphthalene disulfonates, etc. These salts can be prepared by methods known in the art.
[0127] "Pharmaceutically acceptable base addition salt" refers to a salt formed with an inorganic base or an organic base that can maintain the biological effectiveness of the free acid without other side effects. Salts derived from inorganic bases include, but are not limited to, sodium salts, potassium salts, lithium salts, ammonium salts, calcium salts, magnesium salts, iron salts, zinc salts, copper salts, manganese salts, aluminum salts, and the like. Preferred inorganic salts are ammonium salts, sodium salts, potassium salts, calcium salts, and magnesium salts, preferably sodium salts. The salt derived from organic base includes but is not limited to the following salt: primary amines, secondary amines and tertiary amines, substituted amines, including natural substituted amines, cyclic amines and basic ion exchange resins, such as ammonia, isopropylamine, trimethylamine, diethylamine, triethylamine, tripropylamine, ethanolamine, diethanolamine, triethanolamine, dimethylethanolamine, 2-dimethylaminoethanol, 2-diethylaminoethanol, dicyclohexylamine, lysine, arginine, histidine, caffeine, procaine, choline, betaine, ethylenediamine, glucosamine, methylglucosamine, theobromine, purine, piperazine, piperidine, N-ethylpiperidine, polyamine resins, etc. Preferred organic bases include isopropylamine, diethylamine, ethanolamine, trimethylamine, dicyclohexylamine, choline and caffeine. These salts can be prepared by methods known in the art.
[0128] As described herein, the compounds of the present invention may optionally be substituted with one or more substituents, such as the general formula compounds above, or as specific examples in the embodiments, subclasses, and classes of compounds encompassed by the present invention. In general, the term "substituted" means that one or more hydrogen atoms in a given structure are replaced by a specific substituent. Unless otherwise indicated, an optional substituted group may have a substituent substituted at each substitutable position of the group. When more than one position in a given structural formula can be substituted with one or more substituents selected from a specific group, the substituents may be substituted at each position in the same or different manner.
[0129] In addition, it should be noted that, unless explicitly stated otherwise, the description methods used throughout this article, "each... and... are independently", "... and... are each independently", and "... and... are respectively independently" are interchangeable and should be understood in a broad sense, which can mean that in different groups, the specific options expressed by the same symbols do not affect each other, or that in the same group, the specific options expressed by the same symbols do not affect each other.
[0130] In the present invention, the terms "optionally", "optional" or "optionally" generally mean that the subsequently described event or situation can but does not necessarily occur, and the description includes cases where the event or situation occurs and cases where it does not occur.
[0131] In various parts of this specification, the substituents of the compounds disclosed in the present invention are disclosed according to group types or ranges. It is particularly pointed out that the present invention includes each independent subcombination of the individual members of these group types and ranges. For example, the term "C 1-6 "Alkyl" refers specifically to methyl, ethyl, C 3 Alkyl, C 4 Alkyl, C 5 Alkyl and C 6 alkyl.
[0132] The term "alkyl" used in the present invention includes saturated straight or branched monovalent hydrocarbon groups of 1 to 20 carbon atoms, wherein the alkyl group may be independently optionally substituted with one or more substituents described in the present invention. In some embodiments, the alkyl group contains 1 to 12 carbon atoms, in other embodiments, the alkyl group contains 1 to 10 carbon atoms, in other embodiments, the alkyl group contains 1 to 8 carbon atoms, in other embodiments, the alkyl group contains 1 to 6 carbon atoms, in other embodiments, the alkyl group contains 1 to 4 carbon atoms, and in other embodiments, the alkyl group contains 1 to 3 carbon atoms. Further examples of alkyl groups include, but are not limited to, methyl (Me, -CH 3 ), ethyl (Et, -CH 2 CH 3 ), n-propyl (n-Pr, -CH 2 CH 2 CH 3 ), isopropyl (i-Pr, -CH (CH 3 ) 2 ), n-butyl (n-Bu, -CH 2 CH 2 CH 2 CH 3 ), 2-methylpropyl or isobutyl (i-Bu, -CH 2 CH(CH 3 ) 2 ), 1-methylpropyl or sec-butyl (s-Bu, -CH(CH 3 )CH 2 CH 3 ), tert-butyl (t-Bu, -C(CH 3 ) 3 ), n-pentyl (-CH 2 CH 2 CH 2 CH 2 CH 3 ), 2-pentyl (-CH(CH 3 )CH 2 CH 2 CH 3), 3-pentyl (-CH(CH 2 CH 3 ) 2 ), 2-methyl-2-butyl (-C(CH 3 ) 2 CH 2 CH 3 ), 3-methyl-2-butyl (-CH(CH 3 )CH(CH 3 ) 2 ), 3-methyl-1-butyl (-CH 2 CH 2 CH(CH 3 ) 2 ), 2-methyl-1-butyl (-CH 2 CH(CH 3 )CH 2 CH 3 ), n-hexyl (-CH 2 CH 2 CH 2 CH 2 CH 2 CH 3 ), 2-hexyl (-CH(CH 3 )CH 2 CH 2 CH 2 CH 3 )、3-hexyl(-CH(CH 2 CH 3 )(CH 2 CH 2 CH 3 ))、2-methyl-2-pentyl (-C(CH 3 ) 2 CH 2 CH 2 CH 3 ), 3-methyl-2-pentyl (-CH(CH 3 )CH(CH 3 )CH 2 CH 3 ), 4-methyl-2-pentyl (-CH(CH 3 )CH 2 CH(CH 3 ) 2 ), 3-methyl-3-pentyl (-C(CH 3 )(CH 2 CH 3 ) 2 ), 2-methyl-3-pentyl (-CH(CH 2 CH 3 )CH(CH3 ) 2 )、2,3-dimethyl-2-butyl (-C(CH 3 ) 2 CH(CH 3 ) 2 )、3,3-dimethyl-2-butyl (-CH(CH 3 )C(CH 3 ) 3 ), n-heptyl, n-octyl, n-nonyl, n-heptyl, and the like.
[0133] The term "alkoxy" means an alkyl group attached to the rest of the molecule via an oxygen atom, wherein the alkyl group has the meaning as described herein. Unless otherwise specified, the alkoxy group contains 1-12 carbon atoms. In some embodiments, the alkoxy group contains 1-8 carbon atoms; in other embodiments, the alkoxy group contains 1-6 carbon atoms; in other embodiments, the alkoxy group contains 1-4 carbon atoms; in yet other embodiments, the alkoxy group contains 1-3 carbon atoms. The alkoxy group may be optionally substituted with one or more substituents described herein.
[0134] Examples of alkoxy groups include, but are not limited to, methoxy (MeO, -OCH 3 ), ethoxy (EtO, -OCH 2 CH 3 ), 1-propoxy (n-PrO, n-propoxy, -OCH 2 CH 2 CH 3 )、2-propoxy(i-PrO,i-propoxy,-OCH(CH 3 ) 2 )、1-butoxy(n-BuO,n-butoxy,-OCH 2 CH 2 CH 2 CH 3 ), 2-methyl-l-propoxy (i-BuO, i-butoxy, -OCH 2 CH(CH 3 ) 2 ), 2-butoxy(s-BuO,s-butoxy,-OCH(CH 3 )CH 2 CH 3 ), 2-methyl-2-propoxy(t-BuO,t-butyloxy,-OC(CH 3 ) 3 ), 1-pentyloxy (n-pentyloxy, -OCH 2 CH 2 CH 2 CH2 CH 3 ), 2-pentyloxy (-OCH(CH 3 )CH 2 CH 2 CH 3 ), 3-pentyloxy (-OCH(CH 2 CH 3 ) 2 ), 2-methyl-2-butoxy (-OC(CH 3 ) 2 CH 2 CH 3 ), 3-methyl-2-butoxy(-OCH(CH 3 )CH(CH 3 ) 2 ), 3-methyl-l-butoxy (-OCH 2 CH 2 CH(CH 3 ) 2 ), 2-methyl-1-butoxy (-OCH 2 CH(CH 3 )CH 2 CH 3 )etc.
[0135] The term "alkenyl" refers to a linear or branched monovalent, divalent or polyvalent hydrocarbon group containing 2 to 12 carbon atoms, or 2 to 8 carbon atoms, or 2 to 6 carbon atoms, or 2 to 4 carbon atoms, wherein at least one position of CC is sp 2 double bond, wherein the alkenyl group may be independently unsubstituted or substituted with one or more substituents described herein, including "cis", "trans" or "Z", "E" isomers, specific examples of which include, but are not limited to, vinyl (-CH=CH 2 ), propenyl (-CH=CHCH 3 ), allyl (-CH 2 CH=CH 2 ), wherein the alkenyl groups may independently be unsubstituted or substituted with one or more substituents described herein.
[0136] The term "MM 1 "consisting of ring atoms" means that the cyclic group is composed of MM 1 The term "heterocyclic group" refers to a group consisting of 3-6 ring atoms, wherein the ring atoms include carbon atoms and / or heteroatoms such as O, N, S, and P. For example, "a heterocyclic group consisting of 3-6 ring atoms" refers to a monoheterocyclic group consisting of 3, 4, 5, or 6 ring atoms.
[0137] The term "heterocyclyl" refers to a non-aromatic, saturated or partially unsaturated monocyclic, bicyclic or tricyclic ring system containing 3-12 ring atoms, wherein at least one ring atom is selected from nitrogen, sulfur or oxygen atom. The heterocyclyl group may be optionally substituted with one or more substituents described herein. Unless otherwise specified, the heterocyclyl group may be a carbon group or a nitrogen group, and -CH 2-group may be optionally replaced by -C(=O)- or -C(=S)-. The sulfur atom of the ring may be optionally oxidized to S-oxide. The nitrogen atom of the ring may be optionally oxidized to N-oxide. In some embodiments, the heterocyclic group is a heterocyclic group consisting of 3-12 ring atoms, in some embodiments, the heterocyclic group is a heterocyclic group consisting of 5-10 ring atoms, in some embodiments, the heterocyclic group is a heterocyclic group consisting of 3-6 ring atoms, in some embodiments, the heterocyclic group is a heterocyclic group consisting of 4-6 ring atoms, in some embodiments, the heterocyclic group is a heterocyclic group consisting of 5-6 ring atoms, in other embodiments, the heterocyclic group is a heterocyclic group consisting of 4 atoms, refers to a monovalent or polyvalent, saturated or partially unsaturated, non-aromatic monocyclic ring containing 4 ring atoms, wherein at least one ring atom is selected from nitrogen, sulfur and oxygen atoms. In other embodiments, the heterocyclic group is a 5-atom heterocyclic group, which refers to a monovalent or polyvalent, saturated or partially unsaturated, non-aromatic monocyclic ring containing 5 ring atoms, wherein at least one ring atom is selected from nitrogen, sulfur and oxygen atoms. In other embodiments, the heterocyclic group is a 6-atom heterocyclic group, which refers to a monovalent or polyvalent, saturated or partially unsaturated, non-aromatic monocyclic ring containing 6 ring atoms, wherein at least one ring atom is selected from nitrogen, sulfur and oxygen atoms. "Heterocyclic group" also includes a group formed by fusion of a heterocyclic group with a saturated or partially unsaturated ring or a heterocyclic ring. Examples of heterocycles include, but are not limited to, pyrrolidinyl, tetrahydrofuranyl, dihydrofuranyl, tetrahydrothiophenyl, tetrahydropyranyl, dihydropyranyl, tetrahydrothiopyranyl, piperidinyl, morpholinyl, thiomorpholinyl, thioxanyl, piperazinyl, homopiperazinyl, azetidinyl, oxetanyl, thietanyl, homopiperidinyl, glycidyl, azepanyl, oxetanyl, thiepanyl, oxazepinyl, diazepinyl, thiazepinyl, 2-pyrrolinyl, 3- pyrrolinyl, indolinyl, 2H-pyranyl, 4H-pyranyl, dioxanyl, 1,3-dioxolane, pyrazolinyl, dithianyl, dithiolanyl, dihydrothienyl, pyrazolidinylimidazolinyl, imidazolidinyl, 1,2,3,4-tetrahydroisoquinolinyl, 3-azabicyclo[3.1.0]hexyl, 3-azabicyclo[4.1.0]heptyl, azabicyclo[2.2.2]hexyl, 3H-indolylquinolizinyl and N-pyridylurea. Examples of heterocyclic groups also include 1,1-dioxothiomorpholinyl, examples in which the carbon atoms on the ring are replaced by oxo (=O) include, but are not limited to, pyrimidinedione, 1,2,4-thiadiazole-5(4H)-one, 1,2,4-oxadiazole-5(4H)-one, 1H-1,2,4-triazole-5(4H)-one, and the like, examples in which the carbon atoms on the ring are replaced by a =S group include, but are not limited to, 1,2,4-oxadiazole-5(4H)-thione, 1,3,4-oxadiazole-2(3H)-thione, and the like.
[0138] The term "heteroatom" means one or more O, S, N, P and Si, including any oxidation state of N, S and P; in the form of primary, secondary, tertiary amines and quaternary ammonium salts; or in the form of a nitrogen atom in a heterocyclic ring in which the hydrogen is substituted, for example, N (such as N in 3,4-dihydro-2H-pyrrolyl), NH (such as NH in pyrrolidinyl) or NR (such as NR in N-substituted pyrrolidinyl, wherein R represents a substituent as described in the present invention).
[0139] The terms "alkylsilyl" and "alkylsilyl" refer to a methylsilyl group (-SiH 3 ) groups are independently substituted by 1, 2 or 3 alkyl groups. In some embodiments, the alkylsilyl group is 1, 2 or 3 C 1-12 In some embodiments, the alkylsilyl group is 1, 2 or 3 C 1-9 In some embodiments, the alkylsilyl group is 1, 2 or 3 C 1-6 In some embodiments, the alkylsilyl group is 1, 2 or 3 C 1-4 Alkyl groups are connected to silicon atoms to form lower alkylsilyl groups. In still other embodiments, alkylsilyl groups are 1, 2 or 3 C 1-3 An alkyl group is a lower alkylsilyl group formed by connecting an alkyl group to a silicon atom. Suitable alkylsilyl groups may be monoalkylsilyl, dialkylsilyl or trialkylsilyl. Examples of alkylsilyl groups include, but are not limited to, trimethylsilyl (-Si(CH 3 ) 3 ), triethylsilyl (-Si(CH 2 CH 3 ) 3 ), tri-n-propylsilyl (-Si(CH 2 CH 2 CH 3 ) 3 )etc.
[0140] The term "hydroxy protecting group" refers to an unstable chemical moiety that protects the hydroxyl group from undesirable reactions during one or more synthetic procedures. After the one or more synthetic procedures, the hydroxy protecting group can be selectively removed. Hydroxy protecting groups known in the art are generally described in TH Greene and PGM Wuts, Protective Groups in Organic Synthesis, 3rd Edition, John Wiley & Sons, New York (1999). Examples of hydroxy protecting groups of the present invention include, but are not limited to, C 1-12 alkyl, benzyloxycarbonyl, 4-nitrobenzyloxycarbonyl, 4-bromobenzyloxycarbonyl, 4-methoxybenzyloxycarbonyl, methoxycarbonyl, tert-butoxycarbonyl, isopropoxycarbonyl, biphenylmethoxycarbonyl, 2,2,2-trichloroethoxycarbonyl, 2-(trimethylsilyl)ethoxycarbonyl, 2-furfuryloxycarbonyl, allyloxycarbonyl, acetyl (Ac or -C(O)CH 3 ), formyl, chloroacetyl, trifluoroacetyl, methoxyacetyl, phenoxyacetyl, benzoyl (Bz or -C(O)C 6 H 5 ), C 1-10 Alkyl (methyl, tert-butyl, etc.), 2,2,2-trichloroethyl, 2-trimethylsilylethyl, 1,1-dimethyl-2-propenyl, 3-methyl-3-butenyl, allyl, C 6-10 Aryl C 1-4 Alkyl (such as benzyl, phenethyl, etc.), p-methoxybenzyldiphenylmethyl, triphenylmethyl (triphenylmethyl or trityl), tetrahydrofuranyl, methoxymethyl, methylthiomethyl, benzyloxymethyl, 2,2,2-trichloroethoxymethyl, 2-(trimethylsilyl)ethoxymethyl, methanesulfonyl, p-toluenesulfonyl, C 1-10 Alkylsilyl (such as trimethylsilyl (TMS or -Si(CH 3 ) 3 )), triethylsilyl, triisopropylsilyl, MMTr, DMTr or 4',4',4'-trimethoxytrityl, etc.
[0141] The term "amino protecting group" refers to an unstable chemical moiety that protects the amino group from undesirable reactions during the synthesis procedure. After the one or more synthesis procedures, the amino protecting group as described herein can be selectively removed. Amino protecting groups as known in the art are generally described in TH Greene and PGM Wuts, Protective Groups in Organic Synthesis, the 3rd edition, John Wiley & Sons, New York (1999). The example of amino protecting group includes but is not limited to acetyl, tert-butyloxycarbonyl, 9-fluorenylmethoxycarbonyl and benzyloxycarbonyl etc.
[0142] The term "solid support" specifically refers to any particle, bead or surface on which oligonucleotide synthesis can occur. For example, inorganic solid supports and organic solid supports can be selected for use in embodiments of the present invention. Inorganic solid supports are preferably selected from silica gel and controlled-pore glass beads (Controlled-pore glass, CPG for short). Organic solid supports are resins, preferably macroporous resins, more preferably highly cross-linked polystyrene, Tentagel (graft copolymers composed of low cross-linked polystyrene matrix, polyethylene glycol (PEG or POE) grafted thereon), polyvinyl acetate (PVA), copolymers of Poros (Poros)-polystyrene / divinylbenzene, aminopolyethylene glycol and cellulose etc. Preferred embodiments of the present invention utilize solid supports based on CPG. Many other purchasable solid supports all belong to the present invention. BRIEF DESCRIPTION OF THE DRAWINGS
[0143] Attached Figure 1 The inhibitory effects of the compound DAW30227 (i.e., double-stranded siRNA conjugate S146), the control compound DAW30025 (i.e., double-stranded siRNA conjugate S149) and the vehicle control group (normal saline) on HBsAg in the HBV-Tg mouse model experiment are shown. SD in the figure represents single dose.
[0144] Attached Figure 2 The data show the inhibitory effects of the compound DAW30335 of the present invention (i.e., double-stranded siRNA conjugate S147), the control compound DAW30025 (i.e., double-stranded siRNA conjugate S149), DAW30336 (i.e., siRNA conjugate S151) and the vehicle control group (normal saline) on HBsAg in the AAV mouse model experiment.
[0145] Detailed description of the compounds of the present invention
[0146] The present invention provides a new targeting compound, which can be used to prepare a nucleic acid drug for targeted delivery of oligonucleotides to the liver. The present invention also provides a nucleotide conjugate, a preparation method and an application thereof, which has a higher in vivo delivery efficiency, better stability, higher gene expression inhibition activity in hepatocytes and / or lower toxicity. On the other hand, the present invention further provides an siRNA reagent, a preparation method and an application thereof, which has a higher in vivo delivery efficiency, better stability, higher gene expression inhibition activity in HBV and / or lower toxicity.
[0147] The object of the present invention is to provide a novel double-stranded siRNA, its conjugate, its salt and their uses, and specifically to the use of the double-stranded siRNA and its conjugate of the present invention in the preparation of a drug for treating and / or preventing hepatitis B disease. In addition, the present invention also relates to a novel compound, and the use of the compound in the raw material for solid phase synthesis of DNA nucleotides, the synthetic raw material for siRNA drugs, the research of siRNA drugs, the research of gene function and / or the screening of the whole gene library, especially the use as the synthetic raw material for the double-stranded siRNA drug of the present invention. In addition, the present invention also relates to a novel nucleotide residue, and its use in the research of siRNA drugs, the research of gene function and / or the screening of the whole gene library, and the application as an oligonucleotide embedding group. The double-stranded siRNA and its conjugate of the present invention have higher gene expression inhibition activity and / or lower toxicity to HBV.
[0148] In one aspect, the present invention relates to a double-stranded siRNA, a conjugate thereof, or a salt thereof, wherein the double-stranded siRNA comprises a sense strand and an antisense strand, wherein the double-stranded siRNA comprises one or more Ys (i.e., the double-stranded siRNA of the present invention comprises at least one Y), and the Y is Unless otherwise specified, each nucleotide and Y in the double-stranded siRNA of the present invention are independently modified or unmodified. Optionally, the Y can be at any position in the double-stranded siRNA.
[0149] In some embodiments of the double-stranded siRNA, its conjugate or salt thereof of the present invention, the double-stranded siRNA comprises 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10 Ys.
[0150] In some embodiments of the double-stranded siRNA, its conjugate or salt thereof of the present invention, the double-stranded siRNA comprises 1, 2, 3, 4 or 5 Y. Optionally, the Y can be at any position of the double-stranded siRNA.
[0151] In some embodiments of the double-stranded siRNA, its conjugate or salt thereof of the present invention, the sense strand in the double-stranded siRNA comprises at least one (e.g., 1, 2, 3, 4 or 5) Y. Optionally, the Y can be at any position of the sense strand.
[0152] In some embodiments of the double-stranded siRNA, its conjugate or salt thereof of the present invention, the antisense strand in the double-stranded siRNA comprises at least one (e.g., 1, 2, 3, 4 or 5) Y. Optionally, the Y can be at any position of the antisense strand.
[0153] In some embodiments of the double-stranded siRNA, its conjugate or salt thereof of the present invention, in the double-stranded siRNA, the sense strand comprises 0 or at least one (e.g., 1, 2, 3, 4 or 5) Y, and the antisense strand comprises at least one (e.g., 1, 2, 3, 4 or 5) Y. Optionally, the Y may be at any position of the sense strand or the antisense strand.
[0154] In some embodiments of the double-stranded siRNA, its conjugate or salt according to the present invention, the length of the antisense strand of the double-stranded siRNA according to the present invention does not exceed 30 nucleotides. Preferably, the length of the antisense strand of the double-stranded siRNA according to the present invention does not exceed 23 nucleotides. More preferably, the length of the antisense strand of the double-stranded siRNA according to the present invention does not exceed 21 nucleotides.
[0155] In some embodiments of the double-stranded siRNA, its conjugate or salt according to the present invention, the length of the sense strand of the double-stranded siRNA according to the present invention does not exceed 30 nucleotides. Preferably, the length of the sense strand of the double-stranded siRNA according to the present invention does not exceed 23 nucleotides. More preferably, the length of the sense strand of the double-stranded siRNA according to the present invention does not exceed 19 or 21 nucleotides.
[0156] In some embodiments of the double-stranded siRNA, its conjugate or salt thereof of the present invention, the antisense strand comprises a sequence as shown in 5'-UGUGAAGCGAAGUGCACACUU-3' (SEQ ID NO: 40), or a sequence in which one or more (e.g., 1, 2, 3, 4 or 5) nucleotide residues are replaced with Y in the sequence as shown in SEQ ID NO: 40; wherein each nucleotide and Y in the antisense strand are independently modified or unmodified, and the length of the antisense strand does not exceed 23 nucleotides. Optionally, the Y replacement occurs at any position in the sequence as shown in SEQ ID NO: 40,
[0157] In some embodiments of the double-stranded siRNA, its conjugate or salt thereof of the present invention, the sense strand comprises a sequence as shown in 5'-GUGUGCACUUCGCUUCACA-3' (SEQ ID NO: 20), or a sequence in which one or more (e.g., 1, 2, 3, 4 or 5) nucleotide residues are replaced with Y in the sequence as shown in SEQ ID NO: 20; wherein, each nucleotide and Y in the sense strand are independently modified or unmodified, and the length of the sense strand does not exceed 23 nucleotides. Optionally, the Y replacement occurs at any position in the sequence as shown in SEQ ID NO: 20.
[0158] In some embodiments of the double-stranded siRNA, its conjugate or salt thereof of the present invention, the antisense strand includes a sequence in which one or more (e.g., 1, 2, 3, 4 or 5) nucleotide residues are replaced by Y in the sequence as shown in 5'-UGUGAAGCGAAGUGCACACUU-3' (SEQ ID NO: 40); the sense strand comprises a sequence in which one or more (e.g., 1, 2, 3, 4 or 5) nucleotide residues are replaced by Y in the sequence as shown in SEQ ID NO: 20; wherein the Y replacement occurs at any position in the sequence as shown in SEQ ID NO: 40 or SEQ ID NO: 20, and the lengths of the antisense strand and the sense strand are each independently no more than 23 nucleotides.
[0159] In some embodiments of the double-stranded siRNA, its conjugate or salt thereof of the present invention, 70%, 75%, 80%, 85%, 90% or more of the nucleotides and Y in the sense strand or antisense strand of the double-stranded siRNA are modified.
[0160] In some embodiments of the double-stranded siRNA, its conjugate or salt thereof of the present invention, 70%, 75%, 80%, 85%, 90% or more of the nucleotides and Y in the sense strand and antisense strand of the double-stranded siRNA are modified.
[0161] In some embodiments of the double-stranded siRNA, its conjugate or salt thereof of the present invention, each nucleotide and Y in the double-stranded siRNA is modified.
[0162] In some embodiments of the double-stranded siRNA, its conjugate or its salt of the present invention, the modification is selected from at least one of the following: 2'-methoxy modification (i.e., the hydroxyl group at position 2 of ribose is replaced by a methoxy group), 2'-methoxyethyl modification (i.e., the hydroxyl group at position 2 of ribose is replaced by a methoxyethyl group), 2'-fluoro modification (i.e., the hydroxyl group at position 2 of ribose is replaced by an F group), thiophosphate linkage, 2'-deoxy modification, 2'-amino modification (i.e., the hydroxyl group at position 2 of ribose is replaced by an amino group), locked nucleic acid modification, unlocked nucleic acid modification, ethylene glycol nucleic acid modification and 5'-vinyl phosphate modification.
[0163] In some embodiments of the double-stranded siRNA, its conjugate or its salt thereof of the present invention, the sense strand comprises a sequence in which 0, 1, 2, 3, 4 or 5 nucleotide residues are replaced by Y in the sequence as shown in SEQ ID NO: 20, wherein each nucleotide and Y in the sense strand are each independently modified or unmodified.
[0164] In some embodiments of the double-stranded siRNA, its conjugate or salt thereof of the present invention, the sense strand comprises a sequence in which one nucleotide residue is replaced by Y in the sequence as shown in SEQ ID NO: 20.
[0165] In some embodiments of the double-stranded siRNA, its conjugate or its salt thereof of the present invention, the antisense strand comprises a sequence in which 0, 1, 2, 3, 4 or 5 nucleotide residues are replaced by Y in the sequence as shown in SEQ ID NO: 40, wherein each nucleotide and Y of the antisense strand are independently modified or unmodified.
[0166] In some embodiments of the double-stranded siRNA, its conjugate or salt thereof of the present invention, the antisense strand comprises a sequence in which one nucleotide residue is replaced by Y in the sequence as shown in SEQ ID NO:40.
[0167] In some embodiments of the double-stranded siRNA, its conjugate or its salt of the present invention, wherein the Y replacement occurs at position 1 to 19 of the 5' end of the sequence as shown in SEQ ID NO: 20 (i.e., the Y replacement optionally occurs at position 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18 or 19 of the 5' end of the sequence as shown in SEQ ID NO: 20).
[0168] In some embodiments of the double-stranded siRNA, its conjugate or its salt thereof of the present invention, wherein the Y replacement occurs at position 1 to 21 of the 5' end of the sequence as shown in SEQ ID NO: 40 (i.e., the Y replacement optionally occurs at position 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20 or 21 of the 5' end of the sequence as shown in SEQ ID NO: 40).
[0169] In some embodiments of the double-stranded siRNA, its conjugate or its salt of the present invention, wherein the sense strand comprises 5'-g●u●gu G c ACU A sequence in which 0, 1, 2, 3, 4 or 5 nucleotide residues are replaced by Y in the sequence shown in ucgcuucaca-3' (SEQ ID NO: 19), wherein each nucleotide and Y of the sense chain are independently modified or unmodified, and the Y replacement occurs at positions 1 to 19 of the 5' end of the SEQ ID NO: 19 (i.e., the Y replacement optionally occurs at positions 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18 or 19 of the 5' end of the sequence shown in SEQ ID NO: 19), and the length of the sense chain does not exceed 23 nucleotides.
[0170] In some embodiments of the double-stranded siRNA, its conjugate or salt of the present invention, wherein the antisense strand comprises 5'-u● G ●uga A g CG aagu G c A A sequence in which 0, 1, 2, 3, 4 or 5 nucleotide residues are replaced by Y in the sequence shown in cac●u●u-3' (SEQ ID NO: 36), wherein each nucleotide and Y of the antisense chain are independently modified or unmodified, and the Y replacement occurs at positions 1 to 21 of the 5' end of the antisense chain SEQ ID NO: 36 (i.e., the Y replacement optionally occurs at position 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18 or 19 of the 5' end of the sequence shown in SEQ ID NO: 36), and the length of the antisense chain does not exceed 23 nucleotides.
[0171] In some embodiments of the double-stranded siRNA, its conjugate or salt of the present invention, wherein the antisense strand is contained in 5'-u G ●uga(Agn)g CG aaguG c A A sequence in which 0, 1, 2, 3, 4 or 5 nucleotide residues are replaced by Y in the sequence shown in cac●u●u-3' (SEQ ID NO: 33), wherein each nucleotide and Y of the antisense strand are independently modified or unmodified, and the Y replacement occurs at positions 1 to 21 at the 5' end of the sequence shown in SEQ ID NO: 33 (i.e., the Y replacement optionally occurs at position 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18 or 19 at the 5' end of the sequence shown in SEQ ID NO: 33)), and the length of the antisense strand does not exceed 23 nucleotides.
[0172] Unless otherwise specified, in the context of the present invention, capital letters C, G, U, and A in oligonucleotides or siRNA represent base compositions of natural nucleotides; lowercase letters c, g, u, and a respectively represent that the 2-position of the ribose on the nucleotide represented by the corresponding capital letter is modified by methoxy; an underline under a capital letter represents that the 2-position of the ribose on the nucleotide represented by the letter is modified by fluorine; Agn is adenosine-ethylene glycol nucleic acid; a spacer "●" represents that the two nucleotide residues adjacent to the spacer "●" are connected by a thiophosphate group.
[0173] In some embodiments of the double-stranded siRNA, its conjugate or salt of the present invention, the sense strand comprises one of the following nucleotide sequences:
[0174] SEQ ID NO:1, SEQ ID NO:2, SEQ ID NO:3, SEQ ID NO:4, SEQ ID NO:5, SEQ ID NO:6, SEQ ID NO:7, SEQ ID NO:8, SEQ ID NO:9, SEQ ID NO:10, SEQ ID NO:11, SEQ ID NO:12, SEQ ID NO:13, SEQ ID NO:14, SEQ ID NO:15, SEQ ID NO: 16, SEQ ID NO: 17, SEQ ID NO: 18, SEQ ID NO: 19 and SEQ ID NO: 21;
[0175] The sense strand has a length of no more than 23 nucleotides.
[0176] In some embodiments of the double-stranded siRNA, its conjugate or salt of the present invention, the antisense strand comprises one of the following nucleotide sequences:
[0178] SEQ ID NO:22, SEQ ID NO:23, SEQ ID NO:24, SEQ ID NO:25, SEQ ID NO:26, SEQ ID NO:27, SEQ ID NO:28, SEQ ID NO:29, SEQ ID NO:30, SEQ ID NO:31, SEQ ID NO:32, SEQ ID NO:33, SEQ ID NO:34, SEQ ID NO:35, SEQ ID NO:36, SEQ ID NO:37, SEQ ID NO:38 and SEQ ID NO:39;
[0179] The antisense strand is no longer than 23 nucleotides.
[0180] In some embodiments of the double-stranded siRNA, its conjugate or salt of the present invention, wherein the double-stranded siRNA comprises one of the following:
[0181] A sense strand having a nucleotide sequence as shown in SEQ ID NO: 15 and an antisense strand having a nucleotide sequence as shown in SEQ ID NO: 25, wherein the length of the sense strand and the antisense strand each independently does not exceed 23 nucleotides;
[0182] A sense strand having a nucleotide sequence as shown in SEQ ID NO: 17 and an antisense strand having a nucleotide sequence as shown in SEQ ID NO: 25, wherein the length of the sense strand and the antisense strand each independently does not exceed 23 nucleotides;
[0183] A sense strand having a nucleotide sequence as shown in SEQ ID NO: 15 and an antisense strand having a nucleotide sequence as shown in SEQ ID NO: 26, wherein the length of the sense strand and the antisense strand each independently does not exceed 23 nucleotides;
[0184] A sense strand having a nucleotide sequence as shown in SEQ ID NO: 16 and an antisense strand having a nucleotide sequence as shown in SEQ ID NO: 26, wherein the length of the sense strand and the antisense strand each independently does not exceed 23 nucleotides;
[0185] A sense strand having a nucleotide sequence as shown in SEQ ID NO: 17 and an antisense strand having a nucleotide sequence as shown in SEQ ID NO: 26, wherein the length of the sense strand and the antisense strand each independently does not exceed 23 nucleotides;
[0186] A sense strand having a nucleotide sequence as shown in SEQ ID NO: 15 and an antisense strand having a nucleotide sequence as shown in SEQ ID NO: 27, wherein the length of the sense strand and the antisense strand each independently does not exceed 23 nucleotides;
[0187] A sense strand having a nucleotide sequence as shown in SEQ ID NO: 16 and an antisense strand having a nucleotide sequence as shown in SEQ ID NO: 27, wherein the length of the sense strand and the antisense strand each independently does not exceed 23 nucleotides;
[0188] A sense strand having a nucleotide sequence as shown in SEQ ID NO: 17 and an antisense strand having a nucleotide sequence as shown in SEQ ID NO: 27, wherein the length of the sense strand and the antisense strand each independently does not exceed 23 nucleotides;
[0189] A sense strand having a nucleotide sequence as shown in SEQ ID NO: 16 and an antisense strand having a nucleotide sequence as shown in SEQ ID NO: 28, wherein the length of the sense strand and the antisense strand each independently does not exceed 23 nucleotides;
[0190] A sense strand comprising the nucleotide sequence shown in SEQ ID NO: 17 and an antisense strand comprising the nucleotide sequence shown in SEQ ID NO: 28, wherein the length of the sense strand and the antisense strand each independently does not exceed 23 nucleotides; or
[0191] A sense strand having a nucleotide sequence shown in SEQ ID NO: 18 and an antisense strand having a nucleotide sequence shown in SEQ ID NO: 28, wherein the length of the sense strand and the antisense strand each independently does not exceed 23 nucleotides.
[0192] In some embodiments of the double-stranded siRNA, its conjugate or its salt of the present invention, the double-stranded siRNA is selected from one of S1 to S143 in Table 1. In other embodiments of the double-stranded siRNA, its conjugate or its salt of the present invention, the conjugate of the double-stranded siRNA is selected from S146, S147 and S150 in Table 1.
[0193] Table 1
[0194]
[0195]
[0196]
[0197]
[0198]
[0199] Among them, the capital letters C, G, U, and A represent the base composition of natural nucleotides; the lowercase letters c, g, u, and a respectively represent that the ribose 2 position on the nucleotide represented by the corresponding capital letter is modified by methoxy; the underscore under the capital letter Indicates that the 2nd position of the ribose on the nucleotide represented by the letter is modified by fluorine; the spacer "●" indicates that the two nucleotide residues adjacent to the spacer "●" are connected by thiophosphate groups; Agn is adenosine-glycol nucleic acid (Glycol nucleic acid, GNA); Y in double-stranded siRNA represents
[0200] In some embodiments of the double-stranded siRNA, its conjugate or salt thereof of the present invention, the double-stranded siRNA conjugate comprises the double-stranded siRNA and a conjugated group, that is, the double-stranded siRNA conjugate is a conjugate of the double-stranded siRNA and the conjugated group, wherein the conjugated group includes but is not limited to L-96 or DAW40007-4, and the structures of L-96 and DAW40007-4 are respectively:
[0201]
[0202] In some embodiments of the double-stranded siRNA, its conjugate or salt thereof of the present invention, the conjugated group is conjugated to the 3' end or the 5' end of the sense strand of the double-stranded siRNA.
[0203] In some embodiments of the double-stranded siRNA, its conjugate or salt thereof of the present invention, the conjugated group is conjugated to the 3' end of the sense strand of the double-stranded siRNA.
[0204] In some embodiments of the double-stranded siRNA, its conjugate or salt thereof of the present invention, the double-stranded siRNA is linked to the conjugated group through a phosphate group, a phosphorothioate group or a phosphate group.
[0205] In some embodiments of the double-stranded siRNA, its conjugate or salt of the present invention, the 3' end or 5' end of the sense strand of the double-stranded siRNA is linked to the conjugated group through a phosphate group, a phosphorothioate group or a phosphate group.
[0206] On the other hand, the present invention also relates to a nucleotide residue Y, whose structure is:
[0207] On the other hand, the present invention also relates to a compound having a structure as shown in formula (I), or a stereoisomer, tautomer or acceptable salt of the compound as shown in formula (I),
[0208]
[0209] Among them, each R, Z, Y 1 and R 1 Has the meaning as described in the present invention.
[0210] In some embodiments of the compounds described herein, R 1 is methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl or tert-butyl, each of which is independently optionally substituted with 1, 2, 3 or 4 substituents selected from deuterium, hydroxyl, cyano, F, Cl, Br, I, methoxy, ethoxy, 1-propoxy and 2-propoxy.
[0211] In some embodiments of the compounds described herein, Z and Y 1 are independently H, deuterium, a hydroxyl protecting group, HOC(═O)(CH 2 ) j C(=O)-, MC(=O)(CH 2 ) j C(═O)—, a phosphate group, a thiophosphate group, a phosphite amide group or a hydrogen phosphate group, wherein each j and M has the meanings described in the present invention.
[0212] As long as any Y that can make the compound of the present invention participate in the synthesis of oligonucleotides 1 The active phosphate groups all belong to the present invention, such as phosphate groups, thiophosphate groups, phosphite amide groups or hydrogen phosphate groups, all belong to the content of the present invention, and they can be obtained by the compounds of the present invention through the preparation methods disclosed in the art, such as the preparation methods of the phosphodiester method, phosphotriester method and hydrogen phosphate method described in Section 3 of the master's thesis "Chemical Synthesis of Nucleic Acids and Synthesis and Interference Activity Test of 4'-C-Hydroxy Modified siRNA", and the compounds of the present application can be prepared by the method described in the document Kyle W. Knouse et al. "Unlocking P (V): Reagents for chiral phosphorothioate synthesis" 2018. Pages 6-9.
[0213] The phosphate esters described in the present invention include phosphoric acid diesters and triesters; the thiophosphate esters include phosphoric acid diesters and triesters; the hydrogen phosphate group refers to the group formed by the salt formed by the phosphoric acid group and the base.
[0214] In some embodiments of the compounds of the present invention, M is a solid support, preferably a hydroxyl- or amino-functionalized solid support, more preferably a resin or CPG, further preferably a macroporous resin or CPG, and further preferably an aminomethyl resin, a hydroxyl resin or -NHCPG;
[0215] In some embodiments of the compounds described herein, R is -NHR 2 or -N=CH-NR a R b ; Among them. Each R 2 , R a and R b Has the meaning as described in the present invention.
[0216] In some embodiments of the compounds described herein, R 2 It is an amino protecting group.
[0217] In some embodiments of the compounds described herein, each R a and R b are independently H or an amino protecting group, or R a , R b Together with the N atom to which they are attached, they form a heterocyclic group consisting of 5-6 ring atoms, and each of the heterocyclic groups consisting of 5-6 ring atoms is independently optionally substituted by 1, 2, 3 or 4 substituents selected from deuterium, hydroxyl, cyano, F, Cl, Br, I, methyl, ethyl, n-propyl, isopropyl, methoxy, ethoxy, 1-propoxy and 2-propoxy.
[0218] In some embodiments of the compounds described herein, each j is independently 1, 2, 3, 4 or 5.
[0219] In some embodiments of the compounds described herein, Z and Y 1 each independently represents H, deuterium, benzyloxycarbonyl, 4-nitrobenzyloxycarbonyl, 4-bromobenzyloxycarbonyl, 4-methoxybenzyloxycarbonyl, biphenylmethoxycarbonyl, 2,2,2-trichloroethoxycarbonyl, 2-(trimethylsilyl)ethoxycarbonyl, allyloxycarbonyl, chloroacetyl, trifluoroacetyl, methoxyacetyl, phenoxyacetyl, benzoyl, 2,2,2-trichloroethyl, 2-trimethylsilylethyl, 1,1-dimethyl-2-propenyl, 3-methyl-3-butenyl, allyl, p-methoxybenzyldiphenylmethyl, tetrahydrofuranyl, methoxymethyl, methylthiomethyl, benzyloxymethyl, 2,2,2-trichloroethoxymethyl, 2-(trimethylsilyl)ethoxymethyl, methylsulfonyl, p-toluenesulfonyl, C 1-12 Alkyl, C 1-12 Alkyl C(=O)-, C 1-12 Alkylsilyl, C 6-10 Aryl C1-6 Alkyl, HOC(=O)(CH 2 ) j C(=O)-, MC(=O)(CH 2 ) j C(=O)-, triphenylmethyl, MMTr, DMTr, 4',4',4'-trimethoxytrityl, Among them, j, M, X, R x , R y , R c and R d Has the meaning described in the present invention.
[0220] In some embodiments of the compounds described herein, Z and Y 1 each independently represents H, deuterium, benzyloxycarbonyl, 4-nitrobenzyloxycarbonyl, 4-bromobenzyloxycarbonyl, 4-methoxybenzyloxycarbonyl, biphenylmethoxycarbonyl, 2,2,2-trichloroethoxycarbonyl, 2-(trimethylsilyl)ethoxycarbonyl, allyloxycarbonyl, chloroacetyl, trifluoroacetyl, methoxyacetyl, phenoxyacetyl, benzoyl, 2,2,2-trichloroethyl, 2-trimethylsilylethyl, 1,1-dimethyl-2-propenyl, 3-methyl-3-butenyl, allyl, p-methoxybenzyldiphenylmethyl, tetrahydrofuranyl, methoxymethyl, methylthiomethyl, benzyloxymethyl, 2,2,2-trichloroethoxymethyl, 2-(trimethylsilyl)ethoxymethyl, methylsulfonyl, p-toluenesulfonyl, C 1-10 Alkyl, C 1-10 Alkyl C(=O)-, C 1-10 Alkylsilyl, C 6-10 Aryl C 1-4 Alkyl, HOC(=O)(CH 2 ) j C(=O)-, MC(=O)(CH 2 ) j C(=O)-, triphenylmethyl, MMTr, DMTr, 4',4',4'-trimethoxytrityl, Among them, j, M, X, R x , R y , R c and R d Has the meaning described in the present invention.
[0221] In some embodiments of the compounds described herein, Z and Y 1each independently represents H, deuterium, benzyloxycarbonyl, 4-nitrobenzyloxycarbonyl, 4-bromobenzyloxycarbonyl, 4-methoxybenzyloxycarbonyl, biphenylmethoxycarbonyl, 2,2,2-trichloroethoxycarbonyl, 2-(trimethylsilyl)ethoxycarbonyl, allyloxycarbonyl, chloroacetyl, trifluoroacetyl, methoxyacetyl, phenoxyacetyl, benzoyl, 2,2,2-trichloroethyl, 2-trimethylsilylethyl, 1,1-dimethyl-2-propenyl, 3-methyl-3-butenyl, allyl, p-methoxybenzyldiphenylmethyl, tetrahydrofuranyl, methoxymethyl, methylthiomethyl, benzyloxymethyl, 2,2,2-trichloroethoxymethyl, 2-(trimethylsilyl)ethoxymethyl, methylsulfonyl, p-toluenesulfonyl, C 1-8 Alkyl, C 1-8 Alkyl C(=O)-, C 1-8 Alkylsilyl, phenyl C 1-3 Alkyl, HOC(=O)(CH 2 ) j C(=O)-, MC(=O)(CH 2 ) j C(=O)-, triphenylmethyl, MMTr, DMTr, 4',4',4'-trimethoxytrityl, Among them, j, M, X, R x , R y , R c and R d Has the meaning described in the present invention.
[0222] In some embodiments of the compounds described herein, Z and Y 1 each independently represents H, deuterium, benzyloxycarbonyl, 4-nitrobenzyloxycarbonyl, 4-bromobenzyloxycarbonyl, 4-methoxybenzyloxycarbonyl, biphenylmethoxycarbonyl, 2,2,2-trichloroethoxycarbonyl, 2-(trimethylsilyl)ethoxycarbonyl, allyloxycarbonyl, chloroacetyl, trifluoroacetyl, methoxyacetyl, phenoxyacetyl, benzoyl, 2,2,2-trichloroethyl, 2-trimethylsilylethyl, 1,1-dimethyl-2-propenyl, 3-methyl-3-butenyl, allyl, p-methoxybenzyldiphenylmethyl, tetrahydrofuranyl, methoxymethyl, methylthiomethyl, benzyloxymethyl, 2,2,2-trichloroethoxymethyl, 2-(trimethylsilyl)ethoxymethyl, methylsulfonyl, p-toluenesulfonyl, C 1-6 Alkyl, C 1-6 Alkyl C(=O)-, C 1-6 Alkylsilyl, benzyl, phenethyl, HOC(=O)(CH 2 ) j C(=O)-, MC(=O)(CH 2 ) jC(=O)-, triphenylmethyl, MMTr, DMTr, 4',4',4'-trimethoxytrityl, Among them, j, M, X, R x , R y , R c and R d Has the meaning described in the present invention.
[0223] In some embodiments of the compounds described herein, X is Cl or Br.
[0224] In some embodiments of the compounds described herein, each R x and R y is independently a hydroxy protecting group.
[0225] In some embodiments of the compounds described herein, each R c and R d are independently H or an amino protecting group; or R c , R d Together with the N atom to which they are attached, they form a heterocyclic group consisting of 5-6 ring atoms, and the heterocyclic group consisting of 5-6 ring atoms is independently optionally substituted by 1, 2, 3 or 4 substituents selected from deuterium, hydroxyl, cyano, F, Cl, Br, I, methyl, ethyl, propyl, methoxy, ethoxy, 1-propoxy and 2-propoxy.
[0226] In some embodiments of the compounds described herein, R 2 is 9-fluorenylmethoxycarbonyl, benzyloxycarbonyl, 4-nitrobenzyloxycarbonyl, 4-bromobenzyloxycarbonyl, 4-methoxybenzyloxycarbonyl, biphenylmethoxycarbonyl, 2,2,2-trichloroethoxycarbonyl, 2-(trimethylsilyl)ethoxycarbonyl, allyloxycarbonyl, chloroacetyl, trifluoroacetyl, methoxyacetyl, phenoxyacetyl, benzoyl, methyl, tert-butyl, 2-trimethylsilylethyl, 1,1-dimethyl-2-propenyl, 3-methyl-3-butenyl, allyl, benzyl, p-methoxybenzyldiphenylmethyl, trityl, tetrahydrofuranyl, methoxymethyl, methylthiomethyl, benzyloxymethyl, 2,2,2-trichloroethoxymethyl, 2-(trimethylsilyl)ethoxymethyl, methylsulfonyl, p-toluenesulfonyl, trimethylsilyl, triethylsilyl, triisopropylsilyl, C 1-6 Alkoxy or R 3 C(=O)-, where R 3 Has the meaning described in the present invention.
[0227] In some embodiments of the compounds described herein, each R a and R bare independently H, methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, tert-butyl, methoxy, ethoxy, 1-propoxy, 2-propoxy, 9-fluorenylmethoxycarbonyl, benzyloxycarbonyl, 4-nitrobenzyloxycarbonyl, 4-bromobenzyloxycarbonyl, 4-methoxybenzyloxycarbonyl, biphenylmethoxycarbonyl, 2,2,2-trichloroethoxycarbonyl, 2-(trimethylsilyl)ethoxycarbonyl, allyloxycarbonyl, chloroacetyl, trifluoroacetyl, methoxyacetyl, phenoxyacetyl, benzoyl, 2-trimethylsilylethyl, 1,1-dimethyl-2-propenyl, 3-methyl-3-butenyl, allyl, benzyl, p-methoxybenzyldiphenylmethyl, trityl, tetrahydrofuranyl, methoxymethyl, methylthiomethyl, benzyloxymethyl, 2,2,2-trichloroethoxymethyl, 2-(trimethylsilyl)ethoxymethyl, methanesulfonyl, p-toluenesulfonyl, trimethylsilyl, triethylsilyl, triisopropylsilyl or R 4 C(=O)-, or R a , R b Together with the N atom to which they are attached, they form pyrrolidinyl, morpholinyl, piperidinyl and piperazinyl, each of which is independently optionally substituted with 1, 2, 3 or 4 substituents selected from deuterium, hydroxyl, cyano, F, Cl, Br, I, methoxy, ethoxy, 1-propoxy and 2-propoxy, wherein R 4 Has the meaning described in the present invention.
[0228] In some embodiments of the compounds described herein, each R 3 and R 4 Independently for C 1-6 Alkyl, halogenated C 1-6 Alkyl, C 1-6 Alkoxy, phenyl, halogen-substituted phenyl, C 1-6 Alkylphenyl or benzyl.
[0229] In some embodiments of the compounds described herein, each R 3 and R 4 Independently for C 1-4 Alkyl, halogenated C 1-4 Alkyl, C 1-4 Alkoxy, phenyl, halogen-substituted phenyl, C 1-4 Alkylphenyl or benzyl.
[0230] In some embodiments of the compounds described herein, each R 3 and R 4are independently methyl, ethyl, n-propyl, isopropyl, trifluoromethyl, difluoromethyl, monofluoromethyl, trichloromethyl, dichloromethyl, monochloromethyl, 2,2,2-trichloroethyl, methoxy, ethoxy, 1-propoxy, 2-propoxy, 1-butoxy, 2-methyl-1-propoxy, 2-butoxy, tert-butoxy, phenyl, halogen-substituted phenyl, C 1-3 Alkylphenyl or benzyl.
[0231] In some embodiments of the compounds described herein, each R x and R y are independently benzyloxycarbonyl, 4-nitrobenzyloxycarbonyl, 4-bromobenzyloxycarbonyl, 4-methoxybenzyloxycarbonyl, biphenylmethoxycarbonyl, 2,2,2-trichloroethoxycarbonyl, 2-(trimethylsilyl)ethoxycarbonyl, allyloxycarbonyl, chloroacetyl, trifluoroacetyl, methoxyacetyl, phenoxyacetyl, benzoyl, 2,2,2-trichloroethyl, 2-trimethylsilylethyl, 1,1-dimethyl-2-propenyl, 3-methyl-3-butenyl, allyl, p-methoxybenzyldiphenylmethyl, tetrahydrofuranyl, methoxymethyl, methylthiomethyl, benzyloxymethyl, 2,2,2-trichloroethoxymethyl, 2-(trimethylsilyl)ethoxymethyl, methylsulfonyl, p-toluenesulfonyl, cyano C 1-6 Alkyl, C 1-6 Alkyl, C 1-6 Alkyl C(=O)-, C 1-6 alkylsilyl, phenyl, halogen-substituted phenyl, benzyl or phenethyl.
[0232] In some embodiments of the compounds described herein, each R x and R y are independently benzyloxycarbonyl, 4-nitrobenzyloxycarbonyl, 4-bromobenzyloxycarbonyl, 4-methoxybenzyloxycarbonyl, biphenylmethoxycarbonyl, 2,2,2-trichloroethoxycarbonyl, 2-(trimethylsilyl)ethoxycarbonyl, allyloxycarbonyl, chloroacetyl, trifluoroacetyl, methoxyacetyl, phenoxyacetyl, benzoyl, 2,2,2-trichloroethyl, 2-trimethylsilylethyl, 1,1-dimethyl-2-propenyl, 3-methyl-3-butenyl, allyl, p-methoxybenzyldiphenylmethyl, tetrahydrofuranyl, methoxymethyl, methylthiomethyl, benzyloxymethyl, 2,2,2-trichloroethoxymethyl, 2-(trimethylsilyl)ethoxymethyl, methanesulfonyl, p-toluenesulfonyl, CNCH 2 -、CN(CH 2 ) 2 -、CNCH(CH 3 ) 2 CH 2 -、CN(CH 2 )3 -、CNCH(CH 3 ) 2 CH 2 CH 2 -, methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, tert-butyl, C 1-4 Alkyl C(=O)-, C 1-4 alkylsilyl, phenyl, halogen-substituted phenyl, benzyl or phenethyl.
[0233] In some embodiments of the compounds described herein, each R c and R d are independently methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, tert-butyl, methoxy, ethoxy, 1-propoxy, 2-propoxy, 9-fluorenylmethoxycarbonyl, benzyloxycarbonyl, 4-nitrobenzyloxycarbonyl, 4-bromobenzyloxycarbonyl, 4-methoxybenzyloxycarbonyl, biphenylmethoxycarbonyl, 2,2,2-trichloroethoxycarbonyl, 2-(trimethylsilyl)ethoxycarbonyl, allyloxycarbonyl, chloroacetyl, trifluoroacetyl, methoxyacetyl, phenoxy acetyl, benzoyl, 2-trimethylsilylethyl, 1,1-dimethyl-2-propenyl, 3-methyl-3-butenyl, allyl, benzyl, p-methoxybenzyldiphenylmethyl, trityl, tetrahydrofuranyl, methoxymethyl, methylthiomethyl, benzyloxymethyl, 2,2,2-trichloroethoxymethyl, 2-(trimethylsilyl)ethoxymethyl, methanesulfonyl, p-toluenesulfonyl, trimethylsilyl, triethylsilyl, triisopropylsilyl or R 4 C(=O)-, or R c , R d Together with the N atom to which it is attached, it forms a pyrrolidinyl, morpholinyl, piperidinyl or piperazinyl group, and the pyrrolidinyl, morpholinyl, piperidinyl and piperazinyl groups are independently optionally substituted with 1, 2, 3 or 4 substituents selected from deuterium, hydroxyl, cyano, F, Cl, Br, I, methoxy, ethoxy, 1-propoxy and 2-propoxy.
[0234] In some embodiments of the compounds of the present invention, the compounds of the present invention have a structure as shown in formula (II),
[0235]
[0236] In another aspect of the present invention, the present invention also relates to a pharmaceutical composition, which comprises the double-stranded siRNA, its conjugate or salt thereof according to the present invention, and a pharmaceutically acceptable carrier.
[0237] In another aspect of the present invention, the present invention also relates to the use of the siRNA conjugates, the conjugates thereof and the pharmaceutical compositions described in the present invention in the preparation of drugs for treating and / or preventing hepatitis B disease.
[0238] In another aspect of the present invention, the present invention also relates to the use of the nucleotide residues of the present invention as drugs for siRNA research, gene function research and / or screening of a whole gene library, wherein the structure of the nucleotide residues is:
[0239] In some embodiments of the application of the nucleotide residues described in the present invention, the siRNA drug is the double-stranded siRNA drug described in the present invention.
[0240] In another aspect of the present invention, the present invention also relates to the use of the compounds described in the present invention in raw materials for solid phase synthesis of DNA nucleotides, raw materials for synthesis of oligonucleotide drugs, raw materials for synthesis of siRNA drugs, siRNA drug research, gene function research and / or screening of whole gene libraries.
[0241] In another aspect of the present invention, the present invention also relates to the use of the nucleotide residues of the present invention as oligonucleotide intercalating groups, wherein the oligonucleotide is a nucleotide sequence containing 10 to 50 nucleotides or nucleotide base pairs, and the oligonucleotide can inhibit or block the expression of a gene, and the structure of the nucleotide residues is:
[0242] In some embodiments of the present invention, the nucleotide residues are used as oligonucleotide embedding groups, wherein the gene is the HBV gene.
[0243] In some embodiments of the present invention, the nucleotide residues are used as oligonucleotide intercalating groups, wherein the oligonucleotide is siRNA.
[0244] In some embodiments of the present invention where the nucleotide residues are used as oligonucleotide intercalating groups, the siRNA comprises a sense strand and an antisense strand.
[0245] In some embodiments of the present invention, the nucleotide residues are used as oligonucleotide intercalating groups, wherein the nucleotide residues are only intercalated into the positive strand of the siRNA.
[0246] In some embodiments of the present invention, the nucleotide residues are used as oligonucleotide intercalating groups, wherein the nucleotide residues are only intercalated into the antisense strand of the siRNA.
[0247] In some embodiments of the present invention, the nucleotide residues are used as oligonucleotide intercalating groups, wherein the nucleotide residues are intercalated into the sense strand and the antisense strand of the siRNA.
[0248] In some embodiments of the present invention where the nucleotide residues are used as oligonucleotide intercalating groups, the sense strand of the siRNA comprises a sequence as shown in SEQ ID NO:19.
[0249] In some embodiments of the present invention in which the nucleotide residues are used as oligonucleotide intercalating groups, the antisense strand of the siRNA comprises a sequence as shown in SEQ ID NO:36 or SEQ ID NO:33.
[0250] On the other hand, the present invention also provides a method for inhibiting the expression of a specific gene in liver cells in a patient, which comprises administering the double-stranded siRNA and double-stranded siRNA conjugate of the present invention or a composition thereof to the patient, wherein the nucleic acid ligand conjugate or the composition thereof may be a therapeutically effective amount. Nucleic acid conjugates, preparations, administration and disease treatment methods of the present invention
[0251] The effective amount of the nucleic acid conjugate (such as siRNA conjugate or pharmaceutical composition) of the present invention may vary with the mode of administration and the severity of the disease to be treated. The selection of the preferred effective amount can be determined by a person of ordinary skill in the art based on various factors (e.g., through clinical trials). The factors include, but are not limited to: pharmacokinetic parameters of the active ingredient such as bioavailability, metabolism, half-life, etc.; the severity of the disease to be treated by the patient, the patient's weight, the patient's immune status, the route of administration, etc. For example, depending on the urgency of the treatment situation, several divided doses may be administered daily, for example, four times a day, three times a day, twice a day, once a day, or once every other day, or several doses administered daily may be proportionally reduced.
[0252] The drug can be administered to a subject by any suitable route known in the art, including but not limited to oral or parenteral routes, including intravenous administration, intramuscular administration, subcutaneous administration, transdermal administration, airway administration (aerosol), pulmonary administration, nasal administration, rectal administration and topical administration (including buccal administration and sublingual administration), preferably intravenous injection.
[0253] The pharmaceutical composition disclosed in the present invention includes preparations suitable for parenteral administration. The preparation can be conveniently present in unit dosage form and can be prepared by any method known in the pharmaceutical field. The amount of active ingredient that can be combined with auxiliary materials to prepare a single dose form is generally the amount of siRNA that produces a therapeutic effect. Generally speaking, in units of one percent, the amount is about 1% to about 99% active ingredient, preferably about 5% to about 70%, and most preferably about 10% to about 30%.
[0254] In another aspect of the present invention, the present invention proposes a method for inhibiting the expression or activity of hepatitis B virus genes. According to an embodiment of the present invention, the method comprises: contacting the aforementioned siRNA, the aforementioned siRNA conjugate or the aforementioned pharmaceutical composition with cells. As mentioned above, the aforementioned siRNA and siRNA conjugate can degrade the mRNA of hepatitis B virus and inhibit the expression and replication of HBV. Therefore, the method of the present invention can be used to inhibit the expression or activity of hepatitis B virus genes. For example, the expression or activity of hepatitis B virus genes can be inhibited in animals; or the expression or activity of hepatitis B virus genes can be inhibited for non-disease treatment purposes, such as inhibiting the expression or activity of hepatitis B virus genes in vitro for subsequent research.
[0255] In another aspect of the present invention, the present invention provides a method for preventing and / or treating hepatitis B virus-induced diseases. According to an embodiment of the present invention, the method comprises: administering a pharmaceutically acceptable amount of the aforementioned siRNA, the aforementioned siRNA conjugate, or the aforementioned pharmaceutical composition to a subject. According to an embodiment of the present invention, the method can effectively prevent and / or treat diseases related to hepatitis B virus-induced diseases.
[0256] General synthesis method of the compound, double-stranded siRNA and double-stranded siRNA conjugate of the present invention
[0257] Generally, the compounds and nucleic acid conjugates of the present invention can be prepared by the methods described in the present invention, unless otherwise specified, wherein the substituents are defined as shown in formula (I) and (II). The following reaction schemes and examples are used to further illustrate the content of the present invention.
[0258] In the following examples, all temperatures are in degrees Celsius (°C) unless otherwise indicated. The chromatographic column used was a silica gel column, and the silica gel (200-300 mesh) was purchased from Qingdao Ocean Chemical Plant, NH 2 CPG was purchased from Hebei Dinaxingke. Nuclear magnetic resonance spectroscopy was performed with CDC1 3 DMSO-d 6 , CD 3 OD or acetone-d 6is the solvent (in ppm), TMS (0 ppm) or chloroform (7.25 ppm) is used as the reference standard. When multiple peaks appear, the following abbreviations are used: s (singlet), d (doublet), t (triplet), m (multiplet), br (broadened), dd (doublet of doublets), dt (doublet of triplets), br.s (broadened singlet), q (quartet). The coupling constant J is expressed in Hertz (Hz).
[0259] Low-resolution mass spectrometry (MS) data were determined by an Agilent 6320 series LC-MS spectrometer equipped with a G1312A binary pump and a G1316A TCC (column temperature was maintained at 30 °C). A G1329A autosampler and a G1315B DAD detector were used for analysis, and an ESI source was applied to the LC-MS spectrometer.
[0260] High-resolution mass spectrometry (MS) data were determined by an Agilent 6130 series LC-MS spectrometer equipped with a G1311A quaternary pump and a G1316A TCC (column temperature was maintained at 30 °C). A G1329A autosampler and a G1315D DAD detector were used for analysis, and an ESI source was applied to the HR-MS spectrometer.
[0261] The following abbreviations are used throughout this invention:
[0262] EDCI 1-ethyl-3 (3-dimethylpropylamine) carbodiimide EDCI 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide HOBT 1-Hydroxybenzotriazole EA Ethyl acetate
[0263] TFA Trifluoroacetic acid HOBT 1-Hydroxybenzotriazole
[0264] Py Pyridine DMAP 4-Dimethylaminopyridine
[0265] PE Petroleum ether MsCl Methanesulfonyl chloride
[0266] ACN Acetonitrile TMSOTf Trimethylsilyl trifluoromethanesulfonate Ac 2 O Acetic anhydride THF Tetrahydrofuran
[0267] Boc tert-butyloxycarbonyl mL milliliter
[0268] MeOH methanol min minutes
[0269] DMSO dimethyl sulfoxide M,N,mol / L mole / liter DMF N,N-dimethylformamide h hours
[0270] DCM dichloromethane RT, rt room temperature
[0271] DIPEA N,N-Diisopropylethylamine
[0272] HBTU Benzotriazole-N,N,N',N'-tetramethyluronium hexafluorophosphate DETAILED DESCRIPTION
[0273] The scheme of the present invention will be explained below in conjunction with the examples. Those skilled in the art will understand that the following examples are only used to illustrate the present invention and should not be regarded as limiting the scope of the present invention. In particular, the synthesis of small nucleic acids and the synthesis of nucleic acid conjugates can be synthesized according to the embodiments of the present invention or the routine adjustments in the field. If the specific techniques or conditions are not indicated in the examples, they are carried out according to the techniques or conditions described in the literature in the field or according to the product instructions. The reagents or instruments used without indicating the manufacturer are all conventional products that can be purchased commercially.
[0274] Synthesis method of the compound of the present invention
[0275] The following synthesis scheme lists the general experimental steps for preparing the compounds disclosed in the present invention, including those skilled in the art can make appropriate method modifications or raw material adjustments according to actual conditions to prepare the compounds of the present invention. 1 and R have the meanings as described in the present invention; wherein, Z 1 is a hydroxyl protecting group, Y 2 MC(=O)(CH 2 ) j C(=O)-, phosphate group, thiophosphate group, phosphite amide group or hydrogen phosphate group, wherein M has the meaning as described in the present invention. Unless otherwise specified, the compounds described in the present invention can be prepared by the methods described in the following synthesis schemes.
[0276] Synthesis Scheme 1:
[0277]
[0278] Compound (1-C) can be obtained by referring to the preparation method of Synthesis Scheme 1. First, compound (1-A) is protected by a hydroxyl protecting group to obtain compound (1-B). Compound (1-B) reacts with a suitable phosphoric acid reagent or solid support to obtain compound (1-C) containing an active phosphoric acid group or solid support. Stereoisomers of compound (1-C) can also be obtained by referring to the preparation method of Synthesis Scheme 1.
[0279] Preparation Example
[0280] In the following preparation examples, the inventors describe in detail the preparation process of the compounds of the present invention by taking some of the compounds of the present invention as examples, wherein: For CPG.
[0281] Example 1: Synthesis of Monomers
[0282]
[0283] Step 1: Synthesis of compound 1-2
[0284] (2R,3R,5R)-2-(4-aminopyrrolo[2,1-f][1,2,4]triazine-7-yl)-3,4-dihydroxy-5-(hydroxymethyl)tetrahydrofuran-2-carbonitrile (i.e., compound 1-1) (1.0 g, 3.43 mmol) was added to pyridine (15 mL), the mixture was protected by nitrogen, cooled to -5°C, and then 1,3-dichloro-1,1,3,3-tetraisopropyldisiloxane (1.13 mL, 3.53 mmol) was added dropwise. After the addition, the reaction mixture was heated to 25°C and stirred for 20 hours. The reaction solution was concentrated under reduced pressure to remove the solvent, and the residue was separated and purified by silica gel column chromatography (eluent: PE / EA (v / v) = 2 / 3) to obtain white solid compound 1-2 (1.38 g, 75.3%), MS (ESI, pos.ion) m / z: 534.3 [M+H] + .
[0285] Step 2: Synthesis of Compound 1-3
[0286] Compound 1-2 (1.08 g, 2.02 mmol) and N,N-dimethylformamide dimethyl acetal (0.48 g, 4.04 mmol) were added to toluene (15 mL), heated to 50°C and stirred for 4 h. After the reaction, the mixture was concentrated under reduced pressure to obtain compound 1-3 as a white foamy solid (1.19 g, 100%). MS (ESI, pos.ion) m / z: 589.3 [M+H] + ; 1 H NMR (599 MHz, DMSO-d 6)δ8.95(s,1H),8.15(s,1H),6.90(d,J=4.4Hz,1H),6.80(d,J=4.5Hz,1H), 6.49(d,J=5.7Hz,1H),4.58(dd,J=5.7,4.4Hz,1H),4.23–4.12(m,3H),3.92 (dd,J=13.2,2.5Hz,1H),3.25(s,3H),3.19(s,3H),1.06–1.04(m,7H),1.01 (dd,J=7.2,2.0Hz,6H),0.96(dd,J=8.8,7.0Hz,8H),0.89(t,J=7.6Hz,7H).
[0287] Step 3: Synthesis of Compound 1-4
[0288] Compound 1-3 (0.84 g, 1.43 mmol) was added to N,N-dimethylformamide (10 mL), cooled to 0°C, and then iodomethane (0.41 g, 2.86 mmol) and sodium hydride (0.11 g, 2.86 mmol, 60%) were added in sequence, and stirred at 0°C for 20 min. After the reaction was completed, the reaction solution was poured into saturated NH 4 Cl solution, extracted with EA, concentrated the organic phase, and purified the residue by silica gel column chromatography (EA / PE (v / v) = 1 / 1) to obtain compound 1-4 as a white solid (0.71 g, 83%). MS (ESI, pos.ion) m / z: 603.40 [M+H] + .
[0289] Step 4: Synthesis of Compound 1-5
[0290] Compound 1-4 (5.1 g, 8.46 mmol), tetrahydrofuran (50 mL) and tetrabutylammonium fluoride tetrahydrofuran solution (9.48 mL, 9.48 mmol, 1 M) were mixed and stirred at room temperature for reaction. After the reaction was completed, the mixture was concentrated under reduced pressure and the residue was purified by silica gel column chromatography (MeOH / DCM (v / v) = 1 / 20) to obtain white solid compound 1-5 (2.4 g, 79%). MS (ESI, pos.ion) m / z: 361.3 [M+H] + .
[0291] Step 5: Synthesis of Compound 1-6
[0292] Compound 1-5 (2.4 g, 6.66 mmol), dichloromethane (50 mL), triethylamine (2.02 g, 19.98 mmol) and 4-dimethylaminopyridine (0.081 g, 0.67 mmol) were mixed, then cooled to 0°C, and 4,4'-bismethoxytrityl chloride (2.71 g, 7.99 mmol) was added in batches. The resulting reaction mixture was heated to room temperature and stirred for 3 h. The temperature was lowered to 0°C, and 4,4'-bismethoxytrityl chloride (1.35 g) was added twice, and the reaction was continued to stir at 0°C for 2 h. The reaction system was diluted with MeOH (1 mL) and DCM (100 mL), and washed with saturated sodium bicarbonate solution and saturated sodium chloride solution in turn. The organic phase was dried over anhydrous sodium sulfate and concentrated under reduced pressure. The residue was purified by silica gel column (EA / PE (v / v) = 2 / 1) to obtain a light yellow solid compound 1-6 (4.0 g, 91%). MS (ESI, pos.ion) m / z: 663.7 [M+H] + .
[0293] Step 6: Synthesis of Compound 1
[0294] Compound 1-6 (2.0 g, 3.02 mmol) and 1H-tetrazolyl (0.25 g, 3.62 mmol) were added to dichloromethane (40 mL), and bis(diisopropylamino)(2-cyanoethoxy)phosphine (1.92 mL, 6.04 mmol) was added dropwise under nitrogen protection, and the mixture was stirred at room temperature for 4 h. After the reaction, DCM (20 mL) and saturated sodium bicarbonate solution (10 mL) were added, and the organic phase was washed with saturated brine, dried over anhydrous sodium sulfate, and concentrated under reduced pressure. The residue was purified by silica gel column chromatography (EA / PE (v / v) = 4 / 1) to obtain compound 1 (2.13 g, 82%).
[0295] MS (ESI, pos.ion) m / z: 864.9 [M+H] + ;
[0296] 1 H NMR (400 MHz, CDCl 3)δ8.84(s,1H),8.00(d,J=12.0Hz,1H),7.45–7.39(m,2H),7.34–7.28(m,4H),7.22(qd,J=7.6,6.4,3.5Hz,3H),7.02(dd, J=6.8,4.5Hz,1H),6.92(dd,J=4.6,3.1Hz,1H),6.78(td,J=8.5,4.4Hz,4H),4.93(dd,J=25.0,5.0Hz,1H),4.64–4.43(m, 2H),4.05–3.88(m,2H),3.79(dd,J=3.7,2.4Hz,6H),3.60(d,J=6.3Hz,4H),3.48(dd,J=10.5,3.6Hz,1H),3.27(s,3H),3. 24(s,3H),2.66(d,J=6.4Hz,1H),2.06(s,1H),1.28(t,J=7.1Hz,2H),1.19(dd,J=6.8,4.1Hz,8H),1.04(d,J=6.8Hz,4H).
[0297] 31 P NMR (162 MHz, CDCl 3 )δ150.01,149.80.
[0298] Example 2: Synthesis of carrier (compound DAW40007-3)
[0299]
[0300]
[0301]
[0302] Step 1: Synthesis of compound 2-2
[0303] Compound 2-1 (2.50 g, 28.05 mmol) and triethylamine (7.8 mL, 56.1 mmol) were dissolved in DCM (120 mL), and benzyl chloroformate (9.57 g, 56.1 mmol) was added dropwise at 0°C. After the addition, the reaction mixture was heated to room temperature and stirred for 20 h, and saturated ammonium chloride solution (50 mL) was added for dilution, the liquids were separated, the aqueous phase was discarded, the organic phase was concentrated, and the residue was purified by silica gel column chromatography (MeOH / DCM (V / V) = 1 / 30) to obtain white solid compound 2-2 (2.96 g, 47.2%).
[0304] MS (ESI, pos.ion) m / z: 224.2 [M+H] + ;
[0305] 1 H NMR (400 MHz, CDCl 3 )δ7.37(d,J=4.2Hz,5H),5.11(s,2H),5.00(s,1H),4.19–4.14(m,1H),3.70–3.64(m,2H),3.24 (t,J=6.4Hz,2H),3.15(q,J=4.6Hz,1H),1.90(dq,J=14.2,5.0,4.3Hz,2H),1.77–1.71(m,1H).
[0306] Step 2: Synthesis of compound 2-4
[0307] Compound 2-3 (1.5 g, 4.56 mmol) and compound 2-2 (1.22 g, 5.47 mmol) were dissolved in 1,2-dichloroethane (30 mL), and 3A molecular sieves (2.0 g) were added and stirred at room temperature for 10 min. TMSOTf (0.51 g, 2.28 mmol) was added and the reaction mixture was stirred at room temperature for 18 h. The reaction solution was poured into a saturated sodium bicarbonate solution (100 mL), then extracted with DCM (100 mL), washed with saturated brine (100 mL), dried over anhydrous sodium sulfate, and the solvent was evaporated under reduced pressure. The residue was purified by silica gel column chromatography (PE / EA (V / V) = 2 / 1 to 0 / 1) to obtain a light brown oil compound 2-4 (1.8 g, 71.51%). MS (ESI, pos.ion) m / z: 553.3 [M+H] + .
[0308] Step 3: Synthesis of Compound 2-5
[0309] Compound 2-4 (0.57 g, 1.03 mmol) and palladium carbon (0.11 g, 0.1 mmol, 10%) were added to THF (10 mL), and then TFA (0.12 g, 1.03 mmol) was added, followed by hydrogen replacement three times, and then stirred at room temperature for 19 h in a hydrogen atmosphere. After the reaction was completed, diatomaceous earth was filtered, and the solvent was evaporated under reduced pressure to obtain a light brown oily compound 2-5 (0.55 g, 100.32%). MS (ESI, pos.ion) m / z: 419.3 [M-TFA+H] + .
[0310] Step 4: Synthesis of Compound 2-7
[0311] Compound 2-6 (0.46 g, 2.29 mmol, purchased from Shanghai Bid Pharmaceutical Technology Co., Ltd.) and compound 2-5 (1.16 g, 2.18 mmol) were dissolved in DCM (30 mL), and HOBT (0.46 g, 3.44 mmol), HBTU (1.30 g, 3.44 mmol) and DIPEA (2.66 mL, 16.03 mmol) were added in sequence, and the reaction mixture was reacted at room temperature for 16 h. After the reaction, water (20 mL) and DCM (50 mL × 2) were added in sequence, and the organic phase was washed with saturated sodium bicarbonate solution (30 mL) and saturated brine (20 mL) in sequence, and the solvent was evaporated under reduced pressure. The residue was separated and purified by silica gel column chromatography (MeOH / EA (v / v) = 1 / 20) to obtain a white solid 2-7 (1.0 g, yield 72.7%).
[0312] MS (ESI, pos.ion) m / z: 602.3 [M+H] + ;
[0313] 1 H NMR (400MHz, CD 3 OD)δ5.39–5.33(m,1H),5.07(dd,J=11.2,3.4Hz,1H),4.58(d,J=8.4Hz,1H), 4.21–4.09(m,3H),4.04(t,J=6.7Hz,1H),3.89(dt,J=10.4,5.1Hz,1H),3.60– 3.50(m,1H),3.30–3.13(m,2H),2.16(s,3H),2.04(s,3H),1.97(s,3H),1.94( s,3H),1.67–1.56(m,4H),1.48(s,9H),1.41–1.37(m,2H),1.02–0.98(m,2H).
[0314] Step 5: Synthesis of Compound 2-8
[0315] Compound 2-7 (0.72 g, 1.17 mmol) was dissolved in DCM (8 mL), and then TFA (0.87 mL, 11.7 mmol) was added. The reaction mixture was stirred at 25 °C for 16 h, and the solvent was concentrated to give brown oily compound 2-8 (0.74 g, 103.1%).
[0316] MS (ESI, pos.ion) m / z: 502.2 [M+H] + ;
[0317] 1 H NMR (400MHz, CD 3OD)δ5.36(d,J=3.3Hz,1H),5.08(dd,J=11.3,3.3Hz,1H),4.58(d,J=8.4H z,1H),4.16–4.10(m,3H),4.08–4.02(m,1H),3.92–3.85(m,1H),3.58–3.5 0(m,1H),3.26–3.20(m,2H),2.16(s,3H),2.04(d,J=5.2Hz,6H),1.98(s,3 H),1.97(s,3H),1.61–1.56(m,4H),1.54–1.52(m,2H),1.42–1.38(m,2H).
[0318] Step 6: Synthesis of Compound 2-10
[0319] Compound 2-9 (0.19 g, 0.30 mmol) and compound 2-8 (0.50 g, 0.99 mmol) were dissolved in DCM (30 mL), and then HOBT (0.17 g, 1.26 mmol), HBTU (0.48 g, 1.26 mmol) and DIPEA (0.5 mL, 3.0 mmol) were added in sequence, and the reaction mixture was stirred at 30 ° C for 3 h. After the reaction was completed, water (20 mL) was added to quench the reaction, and then extracted with DCM (100 mL × 2), and the organic phases were combined, and the organic phases were washed with saturated sodium bicarbonate solution (40 mL) and saturated sodium chloride solution (40 mL) in sequence, dried over anhydrous sodium sulfate, and the solvent was evaporated under reduced pressure. The residue was separated and purified by silica gel column chromatography (DCM / MeOH (v / v) = 10 / 1) to obtain white solid compound 2-10 (0.23 g, yield 37%). MS(ESI,pos.ion)m / z:1046.3[M / 2+H] + ;
[0320] 1 H NMR (400MHz, CD 3OD)δ7.78(t,J=5.8Hz,2H),7.38–7.36(m,3H),5.36(d,J=3.4Hz,3H),5.13(s,2H),5.08(dd,J=11.2,3.4Hz,3H),4 .58(d,J=8.4Hz,3H),4.21–4.08(m,9H),4.04(t,J=6.7Hz,3H),3.93–3.82(m,3H),3.73–3.66(m,12H),3.60–3.52 (m,3H),3.29–3.18(m,6H),2.52(t,J=6.0Hz,6H),2.38(t,J=7.4Hz,2H),2.20(t,J=7.7Hz,2H),2.16(s,9H),2.04 (s,9H),1.97(s,9H),1.95(s,9H),1.62–1.56(m,12H),1.50–1.42(m,6H),1.35–1.27(m,16H),1.04–0.97(m,6H).
[0321] Step 7: Synthesis of Compound 2-11
[0322] Compound 2-10 (0.20 g, 0.094 mmol) was dissolved in methanol (10 mL), and then Pd / C (10 mg, 10%) was added, and hydrogen was replaced three times. The reaction mixture was stirred at room temperature for 11 h in a hydrogen atmosphere. After the reaction was completed, the reaction mixture was filtered through diatomaceous earth, and the obtained filtrate was evaporated under reduced pressure to dry the solvent to obtain a white solid compound 2-11 (0.19 g, 100%).
[0323] MS(ESI,pos.ion)m / z:1001.1[M / 2+H] + .
[0324] Step 8: Synthesis of compound DAW40007-1
[0325] Compound 2-11 (0.28 g, 0.14 mmol) was dissolved in DCM (20 mL), and HOBT (0.038 g, 0.28 mmol), HBTU (0.080 g, 0.21 mmol), DIPEA (0.054 g, 0.42 mmol) and compound 13 (0.068 g, 0.16 mmol) were added in sequence. The reaction mixture was stirred at room temperature for 13 h. After the reaction was completed, water (10 mL) was added to quench the reaction, and the mixture was extracted with DCM (20 mL). The organic phase was washed with saturated sodium bicarbonate solution (10 mL) and the mixture was heated to 40 ℃. The solvent was evaporated, and the obtained residue was dissolved in acetonitrile (10 mL), and separated by reverse phase preparative column (acetonitrile / water solution (v / v) = 43% to 60%, 50 min). Salt was added to the solution containing the product after preparative separation to saturate the solution, and the organic phase was separated. The aqueous phase was extracted with acetonitrile (100 mL×2), and the organic phases were combined. The combined organic phases were dried over anhydrous sodium sulfate, and the solvent was evaporated under reduced pressure. Acetonitrile (30 mL) was added to the residue, and it was dried over sodium sulfate, filtered, and the filtrate was concentrated under reduced pressure to obtain a light yellow solid compound DAW40007-1 (0.080 g, yield 24%).
[0326] MS(ESI,neg.ion)m / z:2400.18[MH] - ;
[0327] 1 H NMR (400 MHz, DMSO-d 6)δ8.31(s,3H),7.81(d,J=9.2Hz,3H),7.57(t,J=6.0Hz,3H),7.35–7.26(m,4H),7.20(td,J=8.9,3.0Hz,5H),6.95(s,1H),6.88(ddd,J=8.8,5.8 ,2.2Hz,4H),5.22(d,J=3.4Hz,3H),4.97(dd,J=11.2,3.5Hz,4H),4.49(d,J=8.5Hz,3H),4.40(d,J=4.8Hz,1H),4.15(s,1H),4.07–4.00(m,9H),3 .88(dt,J=11.2,8.8Hz,3H),3.74(s,9H),3.59–3.48(m,12H),3.17(dd, J=8.8,5.0Hz,1H),3.10–2.95(m,8H),2.35(t,J=6.3Hz,6H),2.10(s,9H) ,2.08(s,3H),2.04(d,J=4.7Hz,2H),2.00(s,9H),1.89(s,9H),1.78(s, 9H), 1.40 (d, J=12.2Hz, 17H), 1.31–1.16 (m, 18H), 0.79 (q, J=3.2Hz, 6H).
[0328] Step 9: Synthesis of compound DAW40007-2
[0329] Compound DAW40007-1 (0.080 g, 0.033 mmol) was dissolved in DCM (10 mL), and DIPEA (0.029 mL, 0.17 mmol), succinic anhydride (0.008 g, 0.083 mmol) and DMAP (0.014 g, 0.12 mmol) were added. The mixture was stirred at 40 °C for 5 h, and succinic anhydride (10 mg) was added. After the reaction was continued for 16 h, DCM (10 mL), succinic anhydride (10 mg) and DIPEA (0.05 mL) were added. The mixture was stirred for another 9 h, and then succinic anhydride (10 mg) was added. After the reaction was continued for another 10 h, DCM (20 mL) was added for dilution, and the mixture was washed with saturated sodium bicarbonate solution (10 mL). The aqueous phase was discarded, and the organic phase was dried over anhydrous sodium sulfate. The solvent was concentrated under reduced pressure to obtain a white solid compound DAW40007-2 (0.08 g, 96.07%). MS(ESI,neg.ion)m / z:2500.12[MH] - .
[0330] Step 10: Synthesis of compound DAW40007-3
[0331] Compound DAW40007-2 (0.08 g, 0.032 mmol), HBTU (0.015 g, 0.04 mmol) and DIPEA (0.011 mL, 0.064 mmol) were dissolved in ACN (5 mL) and stirred at room temperature for 5 min. Then the mixture was transferred to a flask containing 0.35 g H 2 N-CPG (purchased from Hebei Dinaxingke) was placed in a solid phase synthesizer and shaken for 22.5 hours. The filter cake was filtered and washed with DCM / MeOH (V / V=9 / 1, 10 mL) and DCM (10 mL), and then dried. The filter cake was diluted with 25% Ac 2 The reaction was stirred in O / Py solution (5 mL) for 3 h, filtered, and the filter cake was rinsed with DCM / MeOH (V / V=9 / 1, 10 mL) and DCM (10 mL) in turn, and dried under reduced pressure to obtain a white solid DAW40007-3 (0.357 g) with a measured loading of 14.95 μmol / g.
[0332] It is well known in the art that DAW40007-4 is the residue after chemical reaction of DAW40007-3, which is covalently bonded to Nucleic acid binding.
[0333] Synthesis of compound L96
[0334]
[0335] Compound L96 was prepared according to the method described in patent application WO2014025805A1.
[0336] The structure of the L96 conjugated group is:
[0337]
[0338] Example 3: Synthesis of double-stranded siRNA and double-stranded siRNA conjugates
[0339] 1. No conjugated group is attached Double Chain siRNA synthesis
[0340] The steps for synthesizing the sense and antisense strands of siRNA without conjugated groups are as follows:
[0341] The synthesis was completed according to the theoretical yield of 1 μmol. Weigh 1 μmol of solid support CPG (purchased from Hebei Dinaxingke). All 2'-modified RNA phosphoramidite monomers and auxiliary reagents were commercially available, and all phosphoramidite monomers were provided in 0.1M anhydrous acetonitrile solution. For oligonucleotides with phosphate backbone thiolation modification, 0.1M DDTT solution was used as the thiolation reagent. 5-Ethylthio-1H-tetrazole acetonitrile solution (0.25M) was used as an activator (purchased from Suzhou Kelema), 0.02M iodine pyridine / water solution was used as an oxidant, and 3% trichloroacetic acid in dichloromethane was used as a deprotection reagent, which was placed in the reagent designated position corresponding to the KA-H8 model DNA / RNA automatic synthesizer. Set the synthesis program and enter the specified oligonucleotide base sequence. After checking that everything is correct, start the cyclic oligonucleotide synthesis. The coupling time for each step is 6 minutes, and the thiolation time is 6 minutes. After automatic circulation, an oligonucleotide containing solid support CPG is obtained.
[0342] The nucleotide containing CPG on the solid support obtained above was blown dry with dry argon, then transferred to a 2mL EP tube, and 28% ammonia solution (1.8mL) was added and heated at 55°C for 5 to 18 hours. Filter, wash the filter cake with water (0.5mL), combine the filtrate, and concentrate under reduced pressure to obtain a white or yellow colloidal solid. After reverse phase preparation and purification, the preparation solution was concentrated, passed through a gel column, and excess salt was removed to obtain an oligonucleotide. The concentration of the obtained oligonucleotide was determined by a micro-ultraviolet spectrophotometer (SPECTRO statNano). Mass spectrometry detection and analysis was completed on the Agilent 6530LC-MS Q-Tof system. After primary scanning, the molecular weight of the nucleic acid was calculated after deconvolution.
[0343] Annealing steps:
[0344] The double-stranded siRNA sense strand synthesized above was mixed with the anti-sense strand synthesized above in equimolar amounts, heated to 95° C., maintained at the temperature for 10 minutes, and then slowly cooled to room temperature, and then freeze-dried to obtain the target double-stranded siRNA.
[0345] 2. Synthesis of siRNA conjugates:
[0346] The synthesis of the antisense strand was obtained by referring to the above-mentioned method for synthesizing the sense strand and antisense strand without conjugation groups.
[0347] Synthesis of the sense strand: The general solid support CPG is replaced with the conjugated group-solid support CPG prepared by the present invention (such as Compound DAW40007-3), and the sense strand of the double-stranded siRNA conjugate of the present invention was prepared by referring to the antisense strand synthesis method.
[0348] Annealing steps:
[0349] The sense strand of the double-stranded siRNA conjugate synthesized above was mixed with the antisense strand synthesized above in equimolar amounts, heated to 95° C., maintained at the temperature for 10 min, and then slowly cooled to room temperature, and then freeze-dried to obtain the target siRNA conjugate.
[0350] The double-stranded siRNA and double-stranded siRNA conjugates synthesized above are shown in Table 1-A.
[0351] Table 1-A: Double-stranded siRNA and double-stranded siRNA conjugates synthesized by the present invention
[0352]
[0353]
[0354]
[0355]
[0356] The capital letters C, G, U, and A represent the base composition of natural nucleotides; the lowercase letters c, g, u, and a represent that the ribose 2 position on the nucleotide represented by the corresponding capital letter is modified by methoxy; the underscores under the capital letters Indicates that the ribose 2 position on the nucleotide represented by the letter is modified by fluorine; the spacer "●" indicates that the two nucleotide residues adjacent to the spacer "●" are connected by a thiophosphate group; Agn is adenosine-glycol nucleic acid (Glycol nucleic acid, GNA); Y in double-stranded siRNA represents X in double-stranded siRNA indicates
[0357] Example 4 Cellular activity and cytotoxicity test of the nucleic acid or conjugate of the present invention
[0358] Hepatoma cells (Hep AD38) were cultured in DMEM medium containing 10% fetal bovine serum and incubated in 5% CO 2 , 37°C constant temperature incubator. When the liver cancer cells are in the logarithmic growth phase and in good condition (70% confluence), they are used for experiments. 1.5×10 4 After 24 h, the cells were transfected with different double-stranded siRNAs of a series of concentrations in Table 1 of Example 3 according to the instructions of RNAiMAX transfection reagent (Thermo Fisher), and then incubated at 37°C and 5% CO 2After incubation for 72 hours under the conditions, HBsAg ELISA kit (Shanghai Kehua) and CCK8 kit (DOJINDO) were used to detect HBsAg expression and cytotoxicity respectively. The double-stranded siRNA reagent of the present invention has good inhibitory activity on HBsA, and is significantly better than the HBsA inhibitory activity of the control S144. It can be seen that the introduction of nucleotide residue Y in the double-stranded siRNA described in the present application has a significant improvement effect on the activity of the double-stranded siRNA, and the cytotoxicity of the double-stranded siRNA described in the present application is small. The results of HBsA inhibitory activity and cytotoxicity of some double-stranded siRNA or its conjugates are shown in Table 2.
[0359] Table 2: Inhibitory activity and cytotoxicity results of partially double-stranded siRNA or conjugates of the present invention
[0360]
[0361] Among them, capital letters C, G, U, and A represent the base composition of natural nucleotides; lowercase letters c, g, u, and a respectively indicate that the 2-position of ribose on the nucleotide represented by the corresponding capital letter is modified by methoxy; the underline under the capital letter indicates that the 2-position of ribose on the nucleotide represented by the letter is modified by fluorine; the spacer "●" indicates that the two nucleotide residues adjacent to the spacer "●" are connected by a thiophosphate group.
[0362] Example 6: Evaluation of anti-HBV activity using the PHH in vitro infection model
[0363] The experimental steps are as follows
[0364] Transfection and dosing: On day 0, adjust the revived PHH to an appropriate density (6.67E+05 cells / ml) and inoculate into a 48-well cell culture plate, 1.32E+05 cells per well. On day 1, add D-type HBV to infect PHH (800GE / cell). On day 2, replace with fresh culture medium. On day 4, discard the cell culture medium, dilute the test substance to the required concentration, and then use Lipofectamine TM RNAiMAX was added to the cells by transfection. The starting concentration of the test substance was 500pM, 5-fold dilution, and 7 concentrations were set, 2 replicates, and the wells with only transfection reagent were used as Medium control. Fresh medium without compound was replaced 4-5 hours after transfection. The final concentration of DMSO in the medium was 2%. On the 6th day, fresh medium without compound was replaced. On the 8th day, the cell supernatant was collected and cell viability was detected using CCK-8.
[0365] Free uptake of drugs: On day 0, the test substance was first diluted to the required concentration with enzyme-free water, with a starting concentration of 500nM, 5-fold dilution, 7 concentrations were set, 2 replicates, and 22μl was added to each well of the cell culture plate. The frozen PHH was revived and adjusted to an appropriate density (6.67E+05cells / ml), 1.32E+05 cells per well; the test substance was freely taken up into the cells while plating. On day 1, the culture medium was replaced and PHH was infected with type D HBV (800GE / cell). On day 2, fresh culture medium without virus and compound was replaced. The final concentration of DMSO in the culture medium was 2%. On days 4 and 6, fresh culture medium without compound was replaced. On day 8, the cell supernatant was collected and cell viability was detected with CCK-8.
[0366] Sample detection: qPCR detection of HBV DNA content in cell culture supernatant; ELISA detection of HBsAg and HBeAg content in cell culture supernatant. The experimental results of the double-stranded siRNA conjugate of the present invention reducing the levels of HBsAg, HBeAg and DNA in cells are shown in Table 3.
[0367] Table 3: Experimental results of the double-stranded siRNA conjugates of the present invention in reducing HBsAg, HBeAg, and DNA levels in cells
[0368]
[0369] The experimental results show that the double-stranded siRNA conjugate S146 has good HBsAg, HBeAg and DNA inhibitory activity. Without the need for transfection, its inhibitory activity against HBsAg, HBeAg and DNA is significantly better than that of the control S148.
[0370] Example 6: Hepatitis B virus transgenic mouse experiment
[0371] 1. HBV-Tg transgenic mouse experiment
[0372] Experimental methods
[0373] Experimental animals: HBV-Tg transgenic mice, C57B / 6N-Tg(1.28HBV) / Vst, SPF-grade male, 6-8 weeks old, 16-20 g, purchased from Beijing Weitongda Biotechnology Co., Ltd., animal production certificate number: SCXK(Beijing)2019-0002. The animals were raised by Beijing Weitongda Biotechnology Co., Ltd. and were kept in individual cages.
[0374] Animal grouping: According to the quantitative detection results of mouse serum HBsAg (primary) and HBeAg (secondary), the animals were stratified and randomly divided into groups, with 5 animals in each group.
[0375] Preparation and administration of test products: Calculate the required amount of drug powder according to the purity of each test product. Add the corresponding physiological saline according to the administration concentration of 0.6 mg / mL, and oscillate to mix until it becomes a colorless and transparent liquid. The day of the first administration is defined as day 0. All groups of animals were given a single dose on day 0, and the subcutaneous administration volume was 5 mL / kg. If blood sampling is required on the day of animal administration, the administration will be performed after blood sampling.
[0376] Main outcome measures: The subjects were weighed and blood was drawn once on the 3rd, 7th, 14th, 21st, 28th and 35th days, and serum was separated for determination of HBsAg and HBeAg levels.
[0377] Serum HBsAg and HBeAg level determination: After blood collection, serum is separated and diluted with PBS solution before being sent for testing. 10 μL of serum is taken from each sample and diluted to 500 μL (50 times dilution) with PBS solution. Serum HBsAg and HBeAg levels are measured using the Hepatitis B e Antigen Assay Kit (Mike Biotech) and the Hepatitis B Surface Antigen Assay Kit (Mike Biotech), respectively.
[0378] Experimental results of HBV-Tg transgenic mice
[0379] The inhibitory effect of the siRNA conjugate of the present invention on HBsAg in the HBV-Tg mouse model experiment is shown in the attached Figure 1 .
[0380] The experimental results showed that compared with the vehicle control group, at a dose of 3 mg / Kg, the test compound DAW30227 (i.e., double-stranded siRNA conjugate S146) had a significant inhibitory effect on HBsAg, and also had a certain inhibitory effect on reducing HBeAg. In addition, the inhibitory activity of double-stranded siRNA conjugate S146 on HBsA was significantly better than that of the control DAW30025 (i.e., siRNA conjugate S149).
[0381] 2. Hepatitis B virus AAV mouse experiment
[0382] Experimental methods:
[0383] Preparation and grouping of rAAV8-1.3HBV / C57BL / 6 mouse model: A mouse animal model of persistent HBV infection was prepared by intravenous injection of rAAV8-1.3HBV (type C) into the tail of C57 mice. The AAV virus injection dose was 1E+11vg / mouse, and blood was collected 6 weeks after virus injection to detect the levels of HBeAg, HBsAg, and ALT in serum. According to the quantitative detection results of mouse serum HBsAg (mainly) and HBeAg (secondary), 35 animals were stratified and randomly divided into 5 groups per group.
[0384] Preparation and administration of test products: Calculate the required amount of drug powder according to the purity of each test product. Add the corresponding physiological saline according to the administration concentration of 0.6 mg / mL, and oscillate to mix until it becomes a colorless and transparent liquid. The day of the first administration is defined as day 0. All groups of animals were given a single dose on day 0, and the subcutaneous administration volume was 5 mL / kg. If blood sampling is required on the day of animal administration, the administration will be performed after blood sampling.
[0385] Main outcome measures: The subjects were weighed and blood was drawn once on the 3rd, 7th, 14th, 21st and 28th days, and serum was separated for determination of HBsAg and HBeAg levels.
[0386] Serum HBsAg and HBeAg level determination: After blood collection, serum is separated and diluted with PBS solution before being sent for testing. 10 μL of serum is taken from each sample and diluted to 500 μL (50 times dilution) with PBS solution. Serum HBsAg and HBeAg levels are measured using the Hepatitis B e Antigen Assay Kit and the Hepatitis B Surface Antigen Assay Kit, respectively.
[0387] Results of HBV AAV mouse experiments
[0388] The inhibitory effect of the siRNA conjugate of the present invention on HBsAg in the Tg / HBV mouse model experiment is shown in the attached Figure 2 .
[0389] The experimental results showed that compared with the vehicle control group, at a dose of 3 mg / Kg, the test compound DAW30335 (i.e., siRNA conjugate S147) had a significant inhibitory effect on HBsAg, and also had a certain inhibitory effect on reducing HBeAg. In addition, the inhibitory activity of siRNA conjugate S147 on HBsAg was significantly better than that of the control DAW30025 (i.e., siRNA conjugate S149) and DAW30336 (i.e., siRNA conjugate S151).
[0390] Example 7: Toxicity experiment of subcutaneous injection of the conjugate of the present application in rats
[0391] Experimental methods:
[0392] Rats were given the drug 5 times for a total of 29 days. Clinical observation was performed. Blood was collected from the abdominal aorta after anesthesia before dissection. Blood biochemistry ALT, AST, ALP, CK, UREA, CREA, TP, ALB, GLU, TBIL, DBIL, CHO, TG, Na, K, Cl, A / G, GLB were tested; hematology WBC, RBC, HB, HCT, MCV, MCH, MCHC, RDW, PLT, MPV, WBC classification and percentage; blood coagulation PT, APTT, FIB. In addition, tissue virology was observed, including weighing organs, aorta, esophagus, stomach, duodenum, cecum, colon, ileum, jejunum, rectum, lung (with main bronchus), mesenteric lymph nodes, pancreas, pituitary, eyeball, thyroid / parathyroid gland, salivary gland, prostate, bladder, seminal vesicle, femur, sternum, skin and muscle at the administration site (marked for the last administration), and grossly observed abnormal tissues.
[0393] Statistical methods: SPSS16.0 was used for statistics. The mean and standard deviation of body weight, blood biochemistry, hematology, organ weight and coefficients of each group were calculated, and the statistics were performed according to the following methods: ① First, the Levene's test method was used to test the homogeneity of the data. If the data were homogeneous (test P>0.05), a one-way analysis of variance (ANOVA) test was performed; if the result of the Levene's test was significant (p≤0.05), a Kruskal-Walis test was performed. ② If the result of the ANOVA test was significant (p≤0.05), a multiple comparison test was further performed using the Dunnett parameter test; if the result of the ANOVA was not significant (p>0.05), the statistics were terminated. ③ If the result of the Kruskal-Walis test was significant (p≤0.05), a rank-transformed Dunnett test was further performed; if the result of the Kruskal-Walis test was not significant (p>0.05), the statistics were terminated. The data of clinical symptom observation, food intake and anatomical observation were not statistically processed.
[0394] Experimental conclusion: The experiment showed that clinical observation, blood biochemistry, hematology, organ weight and tissue pathology results overall showed that the siRNA conjugate of the present invention has good safety.
[0395] Although the present invention has been described in detail above by means of general description, specific implementation methods and tests, it is obvious to those skilled in the art that some modifications or improvements may be made to the present invention. Therefore, these modifications or improvements made without departing from the spirit of the present invention all fall within the scope of protection claimed by the present invention.
Claims
1. A double-stranded siRNA, a conjugate thereof or a salt thereof, in, The double-stranded siRNA comprises a sense strand and an antisense strand, and the double-stranded siRNA comprises one or more Y, wherein Y is Each nucleotide and Y in the double-stranded siRNA is independently modified or unmodified.
2. The double-stranded siRNA, its conjugate or its salt according to claim 1, in, The antisense strand comprises a sequence as shown in 5'-UGUGAAGCGAAGUGCACACUU-3' (SEQ ID NO: 40), or a sequence in which one or more nucleotide residues are replaced by Y in the sequence as shown in SEQ ID NO: 40; wherein each nucleotide and Y in the antisense strand are independently modified or unmodified, and the length of the antisense strand does not exceed 23 nucleotides.
3. The double-stranded siRNA, its conjugate or its salt according to claim 1 or 2, in, The sense strand comprises a sequence as shown in 5'-GUGUGCACUUCGCUUCACA-3' (SEQ ID NO: 20), or a sequence in which one or more nucleotide residues are replaced by Y in the sequence as shown in SEQ ID NO: 20, wherein each nucleotide and Y in the sense strand are independently modified or unmodified, and the length of the sense strand does not exceed 23 nucleotides.
4. The double-stranded siRNA, its conjugate or its salt according to any one of claims 1 to 3, in, 70%, 75%, 80%, 85%, 90% or more of the nucleotides and Y in the sense strand or antisense strand are modified; optionally, every nucleotide and Y in the double-stranded siRNA is modified.
5. The double-stranded siRNA, its conjugate or its salt according to any one of claims 1 to 4, wherein the modification is selected from at least one of the following: 2'-methoxy modification, 2'-methoxyethyl modification, 2'-fluoro modification, thiophosphate linkage, 2'-deoxy modification, 2'-amino modification, locked nucleic acid modification, unlocked nucleic acid modification, ethylene glycol nucleic acid modification and 5'-vinyl phosphate modification.
6. The double-stranded siRNA, its conjugate or its salt according to any one of claims 1 to 5, in, The sense strand comprises a sequence in which 0, 1, 2, 3, 4 or 5 nucleotide residues are replaced with Y in the sequence as shown in SEQ ID NO: 20, wherein each nucleotide and Y in the sense strand are independently modified or unmodified.
7. The double-stranded siRNA, its conjugate or its salt according to any one of claims 1 to 6, in, The antisense strand comprises a sequence in which 0, 1, 2, 3, 4 or 5 nucleotide residues are replaced with Y in the sequence as shown in SEQ ID NO: 40, wherein each nucleotide and Y of the antisense strand are independently modified or unmodified.
8. The double-stranded siRNA, its conjugate or its salt according to any one of claims 1 to 7, in, The Y substitution occurs at positions 1 to 19 at the 5' end of the sequence shown in SEQ ID NO:
20.
9. The double-stranded siRNA, its conjugate or its salt according to any one of claims 1 to 8, in, The Y substitution occurs at positions 1 to 21 at the 5' end of the sequence shown in SEQ ID NO:
40.
10. The double-stranded siRNA, its conjugate or its salt according to any one of claims 1 to 9, in, The positive strand is contained in 5'-g●u●gu G c ACU The sequence shown in ucgcuucaca-3' (SEQ ID NO: 19) is a sequence in which 0, 1, 2, 3, 4 or 5 nucleotide residues are replaced by Y, wherein each nucleotide and Y of the sense chain are independently modified or unmodified, the Y replacement occurs at positions 1 to 19 at the 5' end of the SEQ ID NO: 19, and the length of the sense chain does not exceed 23 nucleotides.
11. The double-stranded siRNA, its conjugate or its salt according to any one of claims 1 to 10, in, The antisense strand contains 5'-u● G ●uga A g CG aagu G c A A sequence in which 0, 1, 2, 3, 4 or 5 nucleotide residues are replaced by Y in the sequence shown in cac●u●u-3' (SEQ ID NO: 36), wherein each nucleotide and Y of the antisense chain are independently modified or unmodified, the Y replacement occurs at the 1st to 21st positions at the 5' end of the antisense chain SEQ ID NO: 36, and the length of the antisense chain does not exceed 23 nucleotides.
12. The double-stranded siRNA, its conjugate or its salt according to any one of claims 1 to 10, in, The antisense strand contains 5'-u● G ●uga(Agn)g CG aagu G c A A sequence in which 0, 1, 2, 3, 4 or 5 nucleotide residues are replaced by Y in the sequence shown in cac●u●u-3' (SEQ ID NO: 33), wherein each nucleotide and Y of the antisense strand are independently modified or unmodified, and the Y replacement occurs at the 1st to 21st positions at the 5' end of the sequence as shown in SEQ ID NO: 33, and the length of the antisense strand does not exceed 23 nucleotides.
13. The double-stranded siRNA, its conjugate or its salt according to any one of claims 1 to 12, wherein the sense strand comprises one of the following nucleotide sequences: SEQ ID NO:1, SEQ ID NO:2, SEQ ID NO:3, SEQ ID NO:4, SEQ ID NO:5, SEQ ID NO:6, SEQ ID NO:7, SEQ ID NO:8, SEQ ID NO:9, SEQ ID NO:10, SEQ ID NO:11, SEQ ID NO:12, SEQ ID NO:13, SEQ ID NO:14, SEQ ID NO:15, SEQ ID NO:16, SEQ ID NO:17, SEQ ID NO:18, SEQ ID NO:19 and SEQ ID NO:21; The sense strand has a length of no more than 23 nucleotides.
14. The double-stranded siRNA, its conjugate or its salt according to any one of claims 1 to 13, wherein the antisense strand comprises one of the following nucleotide sequences: SEQ ID NO:22, SEQ ID NO:23, SEQ ID NO:24, SEQ ID NO:25, SEQ ID NO:26, SEQ ID NO:27, SEQ ID NO:28, SEQ ID NO:29, SEQ ID NO:30, SEQ ID NO:31, SEQ ID NO:32, SEQ ID NO:33, SEQ ID NO:34, SEQ ID NO:35, SEQ ID NO:36, SEQ ID NO:37, SEQ ID NO:38 and SEQ ID NO:39; The sense strand is no longer than 23 nucleotides.
15. The double-stranded siRNA, its conjugate or its salt according to any one of claims 1 to 14, in, The double-stranded siRNA comprises one of the following: A sense strand having a nucleotide sequence as shown in SEQ ID NO: 15 and an antisense strand having a nucleotide sequence as shown in SEQ ID NO: 25, wherein the length of the sense strand and the antisense strand is each independently no more than 23 nucleotides; A sense strand having a nucleotide sequence as shown in SEQ ID NO: 17 and an antisense strand having a nucleotide sequence as shown in SEQ ID NO: 25, wherein the length of the sense strand and the antisense strand is each independently no more than 23 nucleotides; A sense strand having a nucleotide sequence as shown in SEQ ID NO: 15 and an antisense strand having a nucleotide sequence as shown in SEQ ID NO: 26, wherein the length of the sense strand and the antisense strand is each independently no more than 23 nucleotides; A sense strand having a nucleotide sequence as shown in SEQ ID NO: 16 and an antisense strand having a nucleotide sequence as shown in SEQ ID NO: 26, wherein the length of the sense strand and the antisense strand is each independently no more than 23 nucleotides; A sense strand having a nucleotide sequence as shown in SEQ ID NO: 17 and an antisense strand having a nucleotide sequence as shown in SEQ ID NO: 26, wherein the length of the sense strand and the antisense strand is each independently no more than 23 nucleotides; A sense strand having a nucleotide sequence as shown in SEQ ID NO: 15 and an antisense strand having a nucleotide sequence as shown in SEQ ID NO: 27, wherein the length of the sense strand and the antisense strand is each independently no more than 23 nucleotides; A sense strand comprising the nucleotide sequence shown in SEQ ID NO: 16 and an antisense strand comprising the nucleotide sequence shown in SEQ ID NO: 27, wherein the length of the sense strand and the antisense strand is each independently no more than 23 nucleotides; A sense strand having a nucleotide sequence as shown in SEQ ID NO: 17 and an antisense strand having a nucleotide sequence as shown in SEQ ID NO: 27, wherein the length of the sense strand and the antisense strand is each independently no more than 23 nucleotides; A sense strand comprising the nucleotide sequence shown in SEQ ID NO: 16 and an antisense strand comprising the nucleotide sequence shown in SEQ ID NO: 28, wherein the length of the sense strand and the antisense strand is each independently no more than 23 nucleotides; A sense strand comprising the nucleotide sequence shown in SEQ ID NO: 17 and an antisense strand comprising the nucleotide sequence shown in SEQ ID NO: 28, wherein the length of the sense strand and the antisense strand is each independently no more than 23 nucleotides; or A sense strand having a nucleotide sequence shown in SEQ ID NO: 18 and an antisense strand having a nucleotide sequence shown in SEQ ID NO: 28, wherein the length of the sense strand and the antisense strand is independently no more than 23 nucleotides.
16. The double-stranded siRNA, its conjugate or its salt according to any one of claims 1 to 15, in, The double-stranded siRNA or its conjugate is selected from one of S1 to S143, S146, S147 and S150.
17. The double-stranded siRNA, its conjugate or its salt according to any one of claims 1 to 16, in, The double-stranded siRNA conjugate is a conjugate of the double-stranded siRNA and the conjugation group L96 or DAW40007-4, and the structures of the conjugation group L-96 and DAW40007-4 are respectively:
18. The double-stranded siRNA, its conjugate or its salt according to claim 17, in, The conjugated group is conjugated to the 3' end or 5' end of the sense strand of the double-stranded siRNA, preferably to the 3' end of the sense strand of the double-stranded siRNA.
19. The double-stranded siRNA, its conjugate or its salt according to claim 17 or 18, in, The double-stranded siRNA is linked to the conjugated group via a phosphate group, a phosphorothioate group or a phosphate group.
20. A nucleotide residue Y having the structure:
21. A compound having a structure as shown in formula (I), or a stereoisomer, tautomer or acceptable salt of the compound as shown in formula (I), R 1 is methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl or tert-butyl, each of which is independently optionally substituted with 1, 2, 3 or 4 substituents selected from deuterium, hydroxyl, cyano, F, Cl, Br, I, methoxy, ethoxy, 1-propoxy and 2-propoxy; Z and Y 1 are independently H, deuterium, a hydroxyl protecting group, HOC(═O)(CH 2 ) j C(=O)-, MC(=O)(CH 2 ) j C(═O)—, a phosphate group, a phosphorothioate group, a phosphite amide group, or a hydrogen phosphate group; M is a solid support, preferably a hydroxyl- or amino-functionalized solid support, more preferably a resin or CPG, further preferably a macroporous resin or CPG, further preferably an aminomethyl resin, a hydroxyl resin or -NHCPG; R is -NHR 2 or -N=CH-NR a R b ; R 2 is an amino protecting group; Each R a and R b are independently H or an amino protecting group, or R a , R b Together with the N atom to which they are attached, they form a heterocyclic group consisting of 5-6 ring atoms, wherein each heterocyclic group consisting of 5-6 ring atoms is independently optionally substituted by 1, 2, 3 or 4 substituents selected from deuterium, hydroxyl, cyano, F, Cl, Br, I, methyl, ethyl, n-propyl, isopropyl, methoxy, ethoxy, 1-propoxy and 2-propoxy; in, Each j is independently 1, 2, 3, 4 or 5.
22. The compound according to claim 21, in, Z and Y 1 each independently represents H, deuterium, benzyloxycarbonyl, 4-nitrobenzyloxycarbonyl, 4-bromobenzyloxycarbonyl, 4-methoxybenzyloxycarbonyl, biphenylmethoxycarbonyl, 2,2,2-trichloroethoxycarbonyl, 2-(trimethylsilyl)ethoxycarbonyl, allyloxycarbonyl, chloroacetyl, trifluoroacetyl, methoxyacetyl, phenoxyacetyl, benzoyl, 2,2,2-trichloroethyl, 2-trimethylsilylethyl, 1,1-dimethyl-2-propenyl, 3-methyl-3-butenyl, allyl, p-methoxybenzyldiphenylmethyl, tetrahydrofuranyl, methoxymethyl, methylthiomethyl, benzyloxymethyl, 2,2,2-trichloroethoxymethyl, 2-(trimethylsilyl)ethoxymethyl, methylsulfonyl, p-toluenesulfonyl, C 1-12 Alkyl, C 1-12 Alkyl C(=O)-, C 1-12 Alkylsilyl, C 6-10 Aryl C 1-6 Alkyl, HOC(=O)(CH 2 ) j C(=O)-, MC(=O)(CH 2 ) j C(=O)-, triphenylmethyl, MMTr, DMTr, 4',4',4'-trimethoxytrityl, or Z and Y 1 each independently represents H, deuterium, benzyloxycarbonyl, 4-nitrobenzyloxycarbonyl, 4-bromobenzyloxycarbonyl, 4-methoxybenzyloxycarbonyl, biphenylmethoxycarbonyl, 2,2,2-trichloroethoxycarbonyl, 2-(trimethylsilyl)ethoxycarbonyl, allyloxycarbonyl, chloroacetyl, trifluoroacetyl, methoxyacetyl, phenoxyacetyl, benzoyl, 2,2,2-trichloroethyl, 2-trimethylsilylethyl, 1,1-dimethyl-2-propenyl, 3-methyl-3-butenyl, allyl, p-methoxybenzyldiphenylmethyl, tetrahydrofuranyl, methoxymethyl, methylthiomethyl, benzyloxymethyl, 2,2,2-trichloroethoxymethyl, 2-(trimethylsilyl)ethoxymethyl, methylsulfonyl, p-toluenesulfonyl, C 1-10 Alkyl, C 1-10 Alkyl C(=O)-, C 1-10 Alkylsilyl, C 6-10 Aryl C 1-4 Alkyl, HOC(=O)(CH 2 ) j C(=O)-, MC(=O)(CH 2 ) j C(=O)-, triphenylmethyl, MMTr, DMTr, 4',4',4'-trimethoxytrityl, or Z and Y 1 each independently represents H, deuterium, benzyloxycarbonyl, 4-nitrobenzyloxycarbonyl, 4-bromobenzyloxycarbonyl, 4-methoxybenzyloxycarbonyl, biphenylmethoxycarbonyl, 2,2,2-trichloroethoxycarbonyl, 2-(trimethylsilyl)ethoxycarbonyl, allyloxycarbonyl, chloroacetyl, trifluoroacetyl, methoxyacetyl, phenoxyacetyl, benzoyl, 2,2,2-trichloroethyl, 2-trimethylsilylethyl, 1,1-dimethyl-2-propenyl, 3-methyl-3-butenyl, allyl, p-methoxybenzyldiphenylmethyl, tetrahydrofuranyl, methoxymethyl, methylthiomethyl, benzyloxymethyl, 2,2,2-trichloroethoxymethyl, 2-(trimethylsilyl)ethoxymethyl, methylsulfonyl, p-toluenesulfonyl, C 1-8 Alkyl, C 1-8 Alkyl C(=O)-, C 1-8 Alkylsilyl, phenyl C 1-3 Alkyl, HOC(=O)(CH 2 ) j C(=O)-, MC(=O)(CH 2 ) j C(=O)-, triphenylmethyl, MMTr, DMTr, 4',4',4'-trimethoxytrityl, or Z and Y 1 each independently represents H, deuterium, benzyloxycarbonyl, 4-nitrobenzyloxycarbonyl, 4-bromobenzyloxycarbonyl, 4-methoxybenzyloxycarbonyl, biphenylmethoxycarbonyl, 2,2,2-trichloroethoxycarbonyl, 2-(trimethylsilyl)ethoxycarbonyl, allyloxycarbonyl, chloroacetyl, trifluoroacetyl, methoxyacetyl, phenoxyacetyl, benzoyl, 2,2,2-trichloroethyl, 2-trimethylsilylethyl, 1,1-dimethyl-2-propenyl, 3-methyl-3-butenyl, allyl, p-methoxybenzyldiphenylmethyl, tetrahydrofuranyl, methoxymethyl, methylthiomethyl, benzyloxymethyl, 2,2,2-trichloroethoxymethyl, 2-(trimethylsilyl)ethoxymethyl, methylsulfonyl, p-toluenesulfonyl, C 1-6 Alkyl, C 1-6 Alkyl C(=O)-, C 1-6 Alkylsilyl, benzyl, phenethyl, HOC(=O)(CH 2 ) j C(=O)-, MC(=O)(CH 2 ) j C(=O)-, triphenylmethyl, MMTr, DMTr, 4',4',4'-trimethoxytrityl, Wherein, X is Cl or Br; Each R x and R y are independently a hydroxy protecting group; Each R c and R d are independently H or an amino protecting group; or R c , R d Together with the N atom to which they are attached, they form a heterocyclic group consisting of 5-6 ring atoms, and the heterocyclic group consisting of 5-6 ring atoms is independently optionally substituted by 1, 2, 3 or 4 substituents selected from deuterium, hydroxyl, cyano, F, Cl, Br, I, methyl, ethyl, propyl, methoxy, ethoxy, 1-propoxy and 2-propoxy.
23. The compound according to claim 21 or 22, in, R 2 is 9-fluorenylmethoxycarbonyl, benzyloxycarbonyl, 4-nitrobenzyloxycarbonyl, 4-bromobenzyloxycarbonyl, 4-methoxybenzyloxycarbonyl, biphenylmethoxycarbonyl, 2,2,2-trichloroethoxycarbonyl, 2-(trimethylsilyl)ethoxycarbonyl, allyloxycarbonyl, chloroacetyl, trifluoroacetyl, methoxyacetyl, phenoxyacetyl, benzoyl, methyl, tert-butyl, 2-trimethylsilylethyl, 1,1-dimethyl-2-propenyl, 3-methyl-3-butenyl, allyl, benzyl, p-methoxybenzyldiphenylmethyl, trityl, tetrahydrofuranyl, methoxymethyl, methylthiomethyl, benzyloxymethyl, 2,2,2-trichloroethoxymethyl, 2-(trimethylsilyl)ethoxymethyl, methylsulfonyl, p-toluenesulfonyl, trimethylsilyl, triethylsilyl, triisopropylsilyl, C 1-6 Alkoxy or R 3 C(=O)-; Each R a and R b are independently H, methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, tert-butyl, methoxy, ethoxy, 1-propoxy, 2-propoxy, 9-fluorenylmethoxycarbonyl, benzyloxycarbonyl, 4-nitrobenzyloxycarbonyl, 4-bromobenzyloxycarbonyl, 4-methoxybenzyloxycarbonyl, biphenylmethoxycarbonyl, 2,2,2-trichloroethoxycarbonyl, 2-(trimethylsilyl)ethoxycarbonyl, allyloxycarbonyl, chloroacetyl, trifluoroacetyl, methoxyacetyl, phenoxyacetyl, benzoyl, 2-trimethylsilylethyl, 1,1-dimethyl-2-propenyl, 3-methyl-3-butenyl, allyl, benzyl, p-methoxybenzyldiphenylmethyl, trityl, tetrahydrofuranyl, methoxymethyl, methylthiomethyl, benzyloxymethyl, 2,2,2-trichloroethoxymethyl, 2-(trimethylsilyl)ethoxymethyl, methanesulfonyl, p-toluenesulfonyl, trimethylsilyl, triethylsilyl, triisopropylsilyl or R 4 C(=O)-, or R a , R b and together with the N atom to which they are attached form a pyrrolidinyl, morpholinyl, piperidinyl or piperazinyl, said pyrrolidinyl, morpholinyl, piperidinyl and or piperazinyl being each independently optionally substituted with 1, 2, 3 or 4 substituents selected from deuterium, hydroxyl, cyano, F, Cl, Br, I, methoxy, ethoxy, 1-propoxy and 2-propoxy; Among them, each R 3 and R 4 Independently for C 1-6 Alkyl, halogenated C 1-6 Alkyl, C 1-6 Alkoxy, phenyl, halogen-substituted phenyl, C 1-6 Alkylphenyl or benzyl; or Each R 3 and R 4 Independently for C 1-4 Alkyl, halogenated C 1-4 Alkyl, C 1-4 Alkoxy, phenyl, halogen-substituted phenyl, C 1-4 Alkylphenyl or benzyl; or Each R 3 and R 4 are independently methyl, ethyl, n-propyl, isopropyl, trifluoromethyl, difluoromethyl, monofluoromethyl, trichloromethyl, dichloromethyl, monochloromethyl, 2,2,2-trichloroethyl, methoxy, ethoxy, 1-propoxy, 2-propoxy, 1-butoxy, 2-methyl-1-propoxy, 2-butoxy, tert-butoxy, phenyl, halogen-substituted phenyl, C 1-3 Alkylphenyl or benzyl.
24. According to any one of claims 22-23, each R x and R y are independently benzyloxycarbonyl, 4-nitrobenzyloxycarbonyl, 4-bromobenzyloxycarbonyl, 4-methoxybenzyloxycarbonyl, biphenylmethoxycarbonyl, 2,2,2-trichloroethoxycarbonyl, 2-(trimethylsilyl)ethoxycarbonyl, allyloxycarbonyl, chloroacetyl, trifluoroacetyl, methoxyacetyl, phenoxyacetyl, benzoyl, 2,2,2-trichloroethyl, 2-trimethylsilylethyl, 1,1-dimethyl-2-propenyl, 3-methyl-3-butenyl, allyl, p-methoxybenzyldiphenylmethyl, tetrahydrofuranyl, methoxymethyl, methylthiomethyl, benzyloxymethyl, 2,2,2-trichloroethoxymethyl, 2-(trimethylsilyl)ethoxymethyl, methylsulfonyl, p-toluenesulfonyl, cyano C 1-6 Alkyl, C 1-6 Alkyl, C 1-6 Alkyl C(=O)-, C 1-6 Alkylsilyl, phenyl, halogen-substituted phenyl, benzyl or phenethyl; or Each R x and R y are independently benzyloxycarbonyl, 4-nitrobenzyloxycarbonyl, 4-bromobenzyloxycarbonyl, 4-methoxybenzyloxycarbonyl, biphenylmethoxycarbonyl, 2,2,2-trichloroethoxycarbonyl, 2-(trimethylsilyl)ethoxycarbonyl, allyloxycarbonyl, chloroacetyl, trifluoroacetyl, methoxyacetyl, phenoxyacetyl, benzoyl, 2,2,2-trichloroethyl, 2-trimethylsilylethyl, 1,1-dimethyl-2-propenyl, 3-methyl-3-butenyl, allyl, p-methoxybenzyldiphenylmethyl, tetrahydrofuranyl, methoxymethyl, methylthiomethyl, benzyloxymethyl, 2,2,2-trichloroethoxymethyl, 2-(trimethylsilyl)ethoxymethyl, methanesulfonyl, p-toluenesulfonyl, CNCH 2 -、CN(CH 2 ) 2 -, CNCH(CH 3 ) 2 CH 2 -、CN(CH 2 ) 3 -, CNCH(CH 3 ) 2 CH 2 CH 2 -, methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, tert-butyl, C 1-4 Alkyl C(=O)-, C 1-4 Alkylsilyl, phenyl, halogen-substituted phenyl, benzyl or phenethyl; Each R c and R d and 1-(2-(4-(6-methyl-1-thio)-1-yl)- ... acetyl, benzoyl, 2-trimethylsilylethyl, 1,1-dimethyl-2-propenyl, 3-methyl-3-butenyl, allyl, benzyl, p-methoxybenzyldiphenylmethyl, trityl, tetrahydrofuranyl, methoxymethyl, methylthiomethyl, benzyloxymethyl, 2,2,2-trichloroethoxymethyl, 2-(trimethylsilyl)ethoxymethyl, methanesulfonyl, p-toluenesulfonyl, trimethylsilyl, triethylsilyl, triisopropylsilyl or R 4 C(=O)-, or R c , R d Together with the N atom to which they are attached, they form a pyrrolidinyl, morpholinyl, piperidinyl or piperazinyl group, each of which is independently optionally substituted with 1, 2, 3 or 4 substituents selected from deuterium, hydroxyl, cyano, F, Cl, Br, I, methoxy, ethoxy, 1-propoxy and 2-propoxy.
25. A compound according to any one of claims 21 to 24, having a structure as shown in formula (II), 26. A pharmaceutical composition comprising the double-stranded siRNA, its conjugate or salt thereof according to any one of claims 1 to 19, and a pharmaceutically acceptable carrier.
27. Use of the double-stranded siRNA conjugate, its conjugate and salt thereof according to any one of claims 1 to 19 or the pharmaceutical composition according to claim 26 in the preparation of a medicament for treating and / or preventing hepatitis B disease.
28. Use of the compound according to any one of claims 21 to 25 in raw materials for solid phase synthesis of DNA nucleotides, raw materials for synthesis of oligonucleotide drugs, raw materials for synthesis of siRNA drugs, siRNA drug research, gene function research and / or screening of whole gene libraries.
29. Use of the nucleotide residues as claimed in claim 20 as oligonucleotide intercalating groups, in, The oligonucleotide is a nucleotide sequence containing 10 to 50 nucleotides or nucleotide base pairs, and the oligonucleotide can inhibit or block the expression of a gene.
30. The use according to claim 29, in, The gene is the HBV gene.
31. The use according to claim 29 or 30, in, The oligonucleotide is siRNA.
32. The use according to any one of claims 31, in, The siRNA includes a sense strand and an antisense strand.
33. The use according to claim 32, in, The nucleotide residues are incorporated only into the sense strand of the siRNA.
34. The use according to claim 32 or 33, in, The nucleotide residues are incorporated only into the antisense strand of the siRNA.
35. The use according to any one of claims 32 to 34, in, The nucleotide residues are incorporated into the sense and antisense strands of the siRNA.
36. The use according to any one of claims 32 to 35, in, The sense strand of the siRNA comprises the sequence shown in SEQ ID NO:
19.
37. The use according to any one of claims 32 to 36, in, The antisense strand of the siRNA comprises the sequence shown in SEQ ID NO:36 or SEQ ID NO:33.
Citation Information
Patent Citations
Methods of treating APOC3 related diseases and disorders
CN114555188A
Carbohydrate conjugated RNA agents and process for their preparation
WO2014025805A1
Oligonucleotide-ligand conjugates and process for their preparation
WO2015006740A2
Cited By
Novel double-stranded siRNA (small interfering ribonucleic acid) as well as conjugate and application thereof
CN122103208A
Novel double-stranded siRNA (small interfering ribonucleic acid) as well as conjugate and application thereof
CN122427208A
Antisense oligonucleotide for inhibiting expression of hepatitis B virus
CN122563953A
Double-chain siRNA agent for targeting AGT and application of double-chain siRNA agent
CN122648410A
Double-stranded siRNA agent targeting Lp(a) and uses thereof
CN122706684A
